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ABSTRACT 
Background and aims 
Cancer is a huge burden to patients, families and to societies in both human and monetary 
terms. Breast (BC), prostate (PC) and colorectal (CRC) cancer are the three most common 
cancer types in Finland. Due to improved survival, health-related quality of life (HRQoL) 
aspects are gaining increasing attention in cancer care. Understanding the cost and HRQoL 
consequences of different treatment choices is critical to be able to use scarce health-care 
resources optimally. The aims of this thesis were to evaluate costs and patient-reported 
HRQoL using three standard instruments (15D, EQ-5D-3L+VAS and EORTC QLQ-C30) in all 
phases of CRC, to assess HRQoL among end-stage BC, PC and CRC patients, and to assess the 
direct economic burden of BC, PC and CRC for patients and analyse what are its implications 
for HRQoL.  
Patients and methods 
A total of 1978 cancer patients from the Helsinki and Uusimaa region having either BC (840), 
PC (630) or CRC (508) participated in this observational cross-sectional study. Patients were 
recruited between 2009 and 2011 from different phases of the disease and divided into five 
mutually exclusive groups according to the stage of their disease: primary treatments; 
rehabilitation; remission; metastatic disease; and palliative care. Patients completed a 
questionnaire, which in addition to the HRQoL questionnaires, enquired about demographic 
factors, health care and informal care resource utilization and work capacity. Furthermore, 
data on direct medical resource use in both primary and secondary care and productivity 
costs were obtained from several different registries. Multivariate regression modelling was 
used to find determinants of deteriorated HRQoL and cost drivers.  
Results 
The HRQoL of CRC patients is fairly good compared to age-, gender- and education-
standardized general population except for those under palliative care. The 15D gave highest 
scores across all states compared to EQ-5D and VAS. Fatigue, pain, age and financial 
difficulties were strongly associated with impaired HRQoL. The total six-month costs of CRC 
varied between disease states from €2106 in rehabilitation to €22,200 in the primary 
treatment state. The costs were highest at the beginning and in the advanced phases of the 
disease. Most of the CRC-related costs were direct medical costs. Productivity costs were 
highest in the primary treatment state (40%) and informal care costs highest in the palliative 
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phase (33%).  Outpatient medication was responsible for the major part of patients’ out-of-
pocket (OOP) payments. High OOP payments were associated with financial difficulties and 
deteriorated HRQoL.  
Conclusions 
All instruments were applicable for the evaluation of HRQoL of cancer patients in all states 
of the disease, however the results the different instruments provided varied significantly. 
Cost of CRC is driven by direct health-care costs in the intense primary care and metastatic 
phase. Financial difficulties are a substantial burden to some and they have a clear negative 
impact on patients’ HRQoL. Outcomes and costs of the care should be measured routinely in 
health care to ensure scare resources are used to maximize patients’ health. 
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TIIVISTELMÄ 
Tutkimuksen tausta ja tavoitteet 
Syöpä on globaalisti valtava haaste: siitä aiheutuu niin potilaille, läheisille kuin yhteiskunnille 
merkittävää inhimillistä ja taloudellista rasitusta. Rinta-, eturauhas- ja kolorektaalisyöpä ovat 
kolme yleisintä syöpätyyppiä Suomessa. Syövän parantuneen ennusteen myötä terveyteen 
liittyvä elämänlaatu on tullut yhä tärkeämmäksi asiaksi syövän hoidossa. Jotta 
terveydenhuollon rajallisia resursseja voidaan kohdentaa mahdollisimman tehokkaasti, tulee 
ymmärtää käytettävissä olevien hoitojen kustannus- ja elämänlaatuvaikutukset. Tämän 
väitöskirjatutkimuksen tavoitteena oli selvittää kolmea yleisesti käytettyä 
elämänlaatumittaria (15D, EQ-5D-3L+VAS and EORTC QLQ-C30) hyödyntäen 
kolorektaalisyöpäpotilaiden elämänlaatu ja kustannukset taudin eri vaiheissa diagnoosista 
palliatiiviseen hoitovaiheeseen saakka, arvioida rinta-, eturauhas- ja 
kolorektaalisyöpäpotilaiden loppuvaiheen elämänlaatua ja selvittää syöpäpotilaille 
sairaudesta aiheutuvia kustannuksia ja taloudellisten vaikeuksien vaikutusta.  
Potilaat ja menetelmät 
Kaikkiaan 1978 rinta- (840), eturauhas- (630) ja kolorektaalisyöpäpotilasta Helsingin ja 
Uudenmaan sairaanhoitopiirin alueelta osallistui tähän havainnoivaan 
poikkileikkaustutkimukseen vuosina 2009-2011. Potilaat rekrytoitiin taudin eri vaiheista ja 
jaettiin syövittäin viiteen eri ryhmään: primaarihoidot, kuntoutumisvaihe, remissio, 
metastaattinen vaihe ja palliatiivinen vaihe. Potilaskyselyssä potilaita selvitettiin 
elämänlaatukyselyiden lisäksi demografisia taustatietoja, terveydenhuollon ja epävirallisten 
palveluiden käyttöä ja työkykyä. Lisäksi tietoa potilaiden terveydenhuollon käytöstä saatiin 
yhdistelemällä erikoissairaanhoidon, perusterveydenhuollon ja KELA:n rekisteritietoja. 
Monimuuttuja-analyysin avulla pyrittää löytämään elämänlaadun tai kustannusten vaihtelua 
selittäviä tekijöitä.  
Tulokset 
Kolorektaalisyöpäpotilaiden raportoima terveyteen liittyvä elämänlaatu verrattain oli hyvä 
verrattuna ikä-, sukupuoli- ja koulutusvakioituun normaali väestöön lukuun ottamatta 
palliatiivisen vaiheen potilaita. 15D-mittari antoi kaikissa syövissä ja taudin vaiheissa 
korkeammat arvot kuin EQ-5D tai VAS. Uupumus, kipu, ikä ja taloudelliset vaikeudet olivat 
selvästi yhteydessä alentuneeseen elämänlaatuun. Syövästä aiheutuneet kustannukset 
vaihtelivat merkittävästi taudin vaiheen mukaan (€2106 – €22 200). Kuuden kuukauden 
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jaksolta korkeimmat kustannukset olivat taudin alkuvaiheessa ja ne nousivat jälleen taudin 
edettyä. Merkittävin osa kustannuksista oli suoria terveydenhuollon kustannuksia. 
Tuottavuuskustannusten osuus oli merkittävin primaarihoidon vaiheessa (40%). Vastaavasti 
epävirallisesta hoidosta aiheutuneet kustannukset olivat suurimmat palliatiivisessa hoidon 
vaiheessa (33%). Avohoidon lääkemenot aiheuttivat potilaiden omavastuutaakasta 
suurimman osan. Potilaiden maksamat korkeat omavastuut olivat yhteydessä syövästä 
aiheutuneisiin taloudellisiin vaikeuksiin ja alentuneeseen elämänlaatuun. 
Johtopäätökset 
Kaikki tutkimuksessa käytetyt mittarit toimivat tässä potilas joukossa, vaikkakin niiden 
antamat tulokset vaihtelivat merkittävästi keskenään. Kolorektaalisyövän kustannukset 
aiheutuvat enimmäkseen suorista terveydenhuollon kustannuksista ja ne olivat korkeimmat 
taudin primaarihoitovaiheessa ja taudin edettyä. Syövästä aiheutuneet talousvaikeudet ovat 
joillekin potilaille merkittäviä ja yhteydessä alentuneeseen elämänlaatuun. Vaikuttavuutta ja 
kustannuksia tulisi seurata terveydenhuollon arjessa säännönmukaisesti, jotta rajalliset 
resurssit voidaan kohdentaa mahdollisimman tehokkaasti potilaiden hyvinvoinnin 
maksimoimiseksi. 
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1 INTRODUCTION  
Cancer is a major global health problem with 18.1 million new cases and 9.6 million deaths 
annually. The rapidly increasing burden of cancer is due to several factors such as aging, 
population growth and social and economic development. Colorectal cancer (CRC) is globally 
the third most common cancer after lung and breast cancer (BC) and second in cancer 
deaths[1]. 
Not only due to cancer but also for other reasons health-care systems around the world are 
struggling with rising costs and limited resources. The need to ensure efficient use of scarce 
resources has made health economic studies increasingly important. Health economics is a 
discipline that studies, for example, how scarce resources are allocated in health care, how 
health should be valued and what defines the demand for and supply of health care. Broadly, 
the question is about applying economic theories and techniques to the health sector.  
Economic evaluation is a treatment-level assessment of health and cost consequences of 
alternative health-care interventions and it provides important information to health-care 
decisionmakers on how to use resources optimally. Economic evaluation is a legal 
prerequisite in most Western countries for new therapies to enter the market and to be 
accessed by patients. It requires standardized ways to value health gains and to measure 
resource use and costs associated with alternative treatment options.  
Measuring health benefits includes changes both in health-related quality of life (HRQoL) 
and length of life. Cancer survival rates have risen dramatically during recent decades due to 
new innovative treatments. As the survival improves, patients live longer with their disease 
and the HRQoL becomes ever more important. However, there is no gold standard for how 
to measure HRQoL and many different instruments have been used.  
Estimates of the costs associated with cancer care are essential for conducting economic 
evaluations of interventions or for assessing the burden of disease at the population level.   
This thesis studies aspects of the health economics of CRC that are important in clinical 
practice and essential in the economic evaluation of new interventions for cancer patients. 
The aim was to assess comprehensively the costs and HRQoL consequences and explore their 
determinants in different states of CRC. Moreover, as a background, a review of the existing 
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CRC-related HRQoL and cost literature and a brief introduction to economic evaluation are 
provided. Also, the financial burden to patients of the three most common cancers is 
explored, as well as HRQoL among end-stage patients.  
Background and review of the literature 
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2 BACKGROUND AND REVIEW OF THE LITERATURE 
A cancer is defined as the abnormal growth of cells, which have the ability to spread to other 
parts of the body. Colorectal cancer originates from the epithelial cells lining the colon or 
rectum of the gastrointestinal tract. 
2.1 EPIDEMIOLOGY OF COLORECTAL CANCER 
Cancer is a major global health problem, the second leading cause of death and its burden is 
increasing. Globally, approximately 9.6 million deaths in 2018 were caused by cancer and 
every sixth death is due to the disease [1]. The economic burden of cancer globally was 
estimated to be 1.16 trillion USD in 2010 [2].  
Measured by the number of new cases per year, the most common cancers globally are: lung 
(2.09 million cases); breast (BC) (2.09 million cases); colorectal (CRC) (1.80 million cases); 
prostate (PC) (1.28 million cases); skin cancer (non-melanoma) (1.04 million cases); stomach 
(1.03 million cases). Leading causes of cancer deaths are lung (1.76 million deaths), colorectal 
(862,000 deaths), stomach (783,000 deaths), liver (782,000 deaths) and breast (627,000 
deaths) cancers[1].  
In Finland, the number of new cases of CRC was 3356 in 2017, of which 53% were men. Of 
the new cases 64 % of the tumours occurred in the colon and 36% in the rectum or 
rectosigmoid. Colon cancer was more common among women and rectum cancer among 
men. In Finland the data have been systematically collected since 1953 by the Finnish Cancer 
Registry. The data show that the number of new cases of CRC has increased substantially 
during this time period (Figure 1) and this trend continues. The number of new cases has 
more than doubled during the last 30 years. Roughly half of this growth is explained by 
population aging and growth[3]. 
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Figure 1.  Number of new cases of CRC in Finland 1953−2017 [3]. 
CRC caused 1368 deaths in Finland in 2017 and the number has been heavily increasing as 
Figure 2 illustrates. However, due to improved diagnostics and treatments the age-
standardized mortality rate has been declining since the 1970s.  
 
Figure 2.  Colorectal-cancer mortality in Finland 1953−2017 [3]. 
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The survival after one year from diagnosis is above 80%. Survival rates for females are higher 
compared to males and for patients with cancer in the rectum or rectosigmoid versus in the 
colon. Five years from diagnosis, on average 64% of males and 69% of females are alive 
(Figure 3) [3]. 
 
Figure 3.  Colorectal-cancer 5-year survival ratio in Finland, age-standardized [3]. 
 
Colorectal cancer diagnostics and prognosis 
Typical symptoms of CRC are, for example, a change in bowel habits, diarrhoea, constipation 
and blood in the stool. Most of the patients are at the time of diagnosis 60−80 years of age. 
The preoperative diagnosis is based on colonoscopy and histopathologic analysis of the 
biopsies. Computed tomography scan or magnetic resonance imaging are used to assess the 
size, location and spread of the cancer. At the time of diagnosis, 20−25% of the cancers are 
local, i.e., stage I. In 40−45% of the cases the cancer has grown through the colon or rectum, 
in 15−20% of the cases it has spread to lymph nodes and in 20−30% of the cases distant 
metastases are present at the time of diagnosis.  
The stage at diagnosis is the single most important predictor of survival (Table 1). The 
classification is based on bowel wall invasion and the presence of lymph node and distant 
metastases. Several systems for classification have been used: TNM, Dukes, Astler−Coller. 
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Currently the most common system for staging is TNM classification. Previously the 
colorectal cancer-specific Dukes system was more often used, but it is no longer 
recommended for clinical practice. The Astler−Coller system is an adapted version of the 
Dukes classification. [4, 5] 
To improve early diagnostics and thus prognosis, most developed countries have 
countrywide CRC screening programmes or are preparing such programmes [6]. In 2013 and 
2014 almost 50% of the 60−68-year-old Finnish citizens were invited to participate in CRC 
screening. Based on these results the national CRC screening programme was started in 
2019. 
Table 1.  Classification systems, distribution at diagnosis and five-year relative survival  
Dukes TNM Features Share of new cases 5-year survival 
A I (T1N0M0) Limited to submucosa 20–25% > 90% 
B II (T2-3N0M0) Limited to muscularis propria (T2) 
Transmural extension (T3) 
40–45% 60–70% 
C III (T1-4N1M0) Involvement of lymph nodes 
- C1 ≤3 
- C2 >3 regional nodes 
15–20% 35–45% 
D IV (T1-4N0-2M1) Distant metastases present  20–30% 0–5% 
 
Treatments of colorectal cancer 
Treatment of CRC includes surgery, medication (chemotherapy, targeted therapy and 
immunotherapy) and radiation based on the stage of the disease. The Comprehensive 
Cancer Centre Finland (FICAN) has published its first national treatment guidelines for 
colorectal cancer [7]. The guidelines are mainly similar to the European Society for Medical 
Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) consensus 
guidelines [8-10]. For cancers stage 0-I, surgery is usually the only treatment needed. For 
stage II disease, where cancer has proliferated through the bowel tissue, in addition to 
surgery, adjuvant chemotherapy might be needed, based on additional risk factors. At stage 
III the surgery includes removal of nearby lymph nodes, and adjuvant chemotherapy is 
recommended: CAPOX (capecitabine and oxaliplatin) or FOLFOX (leucovorin, fluorouracil and 
oxaliplatin). For patients too frail for surgery, radiation/chemotherapy might be an option. 
In stage IV the tumour has spread to distant organs, most commonly to the liver followed by 
the lungs, brain, peritoneum, and distant lymph nodes. In metastatic colorectal cancer 
(mCRC) the treatment algorithms are mostly based on the tumour’s genetic profile, tumour 
Background and review of the literature 
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mutational burden, microsatellite instability, previous treatments and location of the 
primary tumour [7].  
2.2 HRQOL IN CRC 
Improving health is the main purpose of health care. Thus, the ability to quantify health is an 
essential requirement for the assessment of the success of health care. In health care, many 
different measures are used and many of those are not measures of health itself but rather 
intermediate outcomes (Figure 4) [11].  
 
 
Figure 4.  Health measures taxonomy (Adapted from Drummond et al. [11]). 
 
Intermediate outcomes, such as cholesterol level, are useful when assessing which 
treatment option is the most effective but they do not quantify the improvements in health 
as such. HRQoL is a multidimensional concept that combines the different dimensions of 
health. The instruments used to measure HRQoL vary in terms of the dimensions included 
and how they are weighted.  
A health effect measure, which could be used widely in health-care decision-making across 
different diseases, should encompass changes in quality and length of life and be based on 
valuation of possible health states. The most frequently used measure for health gain is 
quality-adjusted life-years (QALYs) gained, which was first introduced in 1968 [12].  
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QALYs gained capture the quantity gains (reduced mortality) and quality gains (reduced 
morbidity) of health in a single measure. Usually the scale for QALYs varies from 0 (death) to 
1 (perfect health). Thus, one QALY is equal to one year lived in perfect health or two years 
lived with a quality weight of 0.5. Also, a loss of health could be used as a basis in economic 
evaluations. The most used measure is the disability-adjusted life-year (DALY) [13].  
To value the different possible health states, the preferences for them should be measured. 
The most widely used techniques are rating scales such as the visual analogue scale (VAS) 
and choice-based methods such as the standard gamble (SG) and the time trade-off (TTO). 
Many scholars claim that choice-based methods should be used whenever possible. VAS is 
the simplest method, where subjects rank their health state on a scale from 0 to 100. The SG 
is based on utility theory [14]. Valuation of a certain health state i is done by offering two 
alternatives: possible immediate recovery from the health state i to perfect health 
(probability p) or immediate death (probability 1-p) vs. remaining in the health state i. The 
preference score is the probability p when the subject is indifferent between the 
alternatives. TTO was developed for health care by Torrance et al. in 1972 [15]. The method 
gives comparable results to the SG, but is easier to administer for the subjects [16]. In TTO a 
subject is offered two alternatives: staying in the health state for time t followed by death 
vs. being in a perfect health for time x. The preference score is calculated as x/t. 
Instruments used to measure HRQoL  
The HRQoL instruments can be classified into generic instruments and disease-specific 
instruments (Figure 4). Generic instruments are designed to be applicable in a wide range of 
different diseases and conditions and are needed when decisions or assessments are made 
between different diseases. Disease-specific measures are tailored for specific diseases, for 
example cancer (EORTC QLQ-C30), and thus the dimensions to be included  are very relevant 
in that setting and the instrument may be more sensitive in two respects: it may exhibit more 
discriminatory power, i.e. be able to detect small differences between individuals or groups, 
and/or be more responsive to changes, i.e. detect small changes over time. Generic 
measures could provide a health profile or preference-based single index values. The latter 
are needed to calculate QALYs. It is impossible to use the SG or the TTO method directly in 
clinical practice to establish single index values for health states, thus pre-scored 
multidimensional health state descriptive systems are mainly used. The most often used 
systems in Finland are the EQ-5D, 15D and SF-6D. Others that are available include the Health 
Background and review of the literature 
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Utilities Index (HUI) [17], the Assessment of Quality of Life (AQoL) [18], the Quality of Well-
Being Scale (QWB) [19] and the Rosser-Kind index [20].  
15D 
The 15D is the most used generic instrument in Finland. It consists of 15 dimensions: 
mobility; vision; hearing; breathing; sleeping; eating; speech; excretion; usual activities; 
mental function; discomfort and symptoms; depression; distress; vitality; and sexual activity 
[21]. Each dimension has a range from 1 (no problems) to 5 (extreme problems). In addition 
to providing a single-index HRQoL score (ranging from 0 to 1), the 15D can also serve as a 
profile instrument depicting patients’ assessment of their HRQoL on each of the 15 
dimensions of health. 15D allows imputing up to three missing values per respondent. The 
minimum clinically important change or difference (MCID) in the 15D score has been 
estimated to be 0.015 [22]. 
EQ-5D 
The EQ-5D is a five-dimensional (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/ depression) instrument. In the original version each dimension has three levels (EQ-
5D-3L, referred to from hereon in as ‘EQ-5D’). The EQ-5D was developed in the 1990s by the 
EuroQol Group. The instrument does not allow calculating the index score if any answer is 
missing. The minimum score depends on the valuation algorithm used. The commonly used 
UK time trade-off (TTO) tariff gives the minimum score –0.594 [23]. The MCID for this 
algorithm is estimated to be 0.08 in cancer [24]. A new five-level version (EQ-5D-5L) was 
launched in 2011 to improve the ability to detect smaller changes in health and to reduce 
the evident ceiling effect [25].  
The EQ-5D questionnaire also includes a VAS, which is the simplest way to express directly 
the patient’s self-perceived evaluation of his/her health state on a vertical scale from 0 
(worst imaginable health state) to 100 (best imaginable health state). For the VAS there is no 
clearly agreed MCID. It has been estimated to range between 7 and 12 [24]. 
SF-6D and SF-36 
The SF (short form)-36 is a 36-item measure which includes eight domains: physical function; 
role limitations owing to physical problems; bodily pain; general health perception; vitality; 
social functioning; role limitations owing to emotional problems; and mental health. Its 
dimensions can be summarized into two summary scores: the physical health component 
summary score (PCS) and the mental health component summary score (MCS) [26]. SF-36 
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itself does not allow to convert its results to health state preferences and QALYs so the 
preference-based SF-6D was developed based partly on the SF-36 questions and was 
introduced by Brazier et al. in 2002 [27]. To use the SF-6D to get a single index value one 
must first use the SF-36 or its short version, the SF-12 questionnaire. 
EORTC QLQ-C30  
The EORTC QLQ-C30 is a cancer-specific HRQoL profile instrument developed by The 
European Organization for Research and Treatment of Cancer. It was developed in the 1980s 
to unify the measuring of cancer patients' physical, psychological and social functions in 
clinical trials. The instrument produces a global health status, five functioning scales 
(physical, role, social, emotional and cognitive functions), three symptom scales (fatigue, 
nausea/vomiting and pain) and six single-symptom items (dyspnoea, insomnia, appetite loss, 
constipation, diarrhoea and financial difficulties) [28]. Although the EORTC QLQ-C30 is one 
of the most used patient-reported outcome measures (PROMs) in cancer, it cannot be used 
in health economic analysis. Based on the EORTC QLQ-C30 questionnaire, a preference-
based measure EORTC-8D has been developed [29]. It has eight dimensions (physical 
functioning, role functioning, social functioning, emotional functioning, pain, fatigue and 
sleep disturbance, nausea, constipation, and diarrhoea) with four or five levels each. 
HRQoL in CRC literature search  
The aim of the literature review was to understand what generic preference-based HRQoL 
measures have been used in CRC, in which study settings and what the implications have 
been. The reporting follows the Preferred Reporting Items of Systematic Reviews and Meta-
Analyses guidelines (PRISMA) [30]. 
Methods 
We used the PubMed database to identify articles about HRQoL and CRC that were published 
between January 2000 and July 2019 in the English language. We used the medical subject 
headings (MeSH) search strategy with the subject term “colorectal neoplasms” combined 
with MeSH major subject term “quality of life”.  
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Figure 5.  Flow diagram of the literature search process of HRQoL articles. 
This yielded 1557 studies of which 226 were review articles and thus excluded. Furthermore, 
congress abstracts were not included. We focused only on single index value instruments 
such as: 15D, EQ-5D, SF-6D, HUI and AQoL and direct measurements with TTO and SG. Using 
these criteria 46 papers were selected for closer review (Figure 5). 
Results of the review 
The type of study, country, number of patients, HRQoL instruments used and the stage of 
patients were recorded (Table 2). Of the 46 publications that were analysed in more depth, 
6 were economic evaluations, 16 clinical trials, 14 observational studies and 10 
methodologic, mainly mapping, studies. The number of HRQoL in CRC publications increased 
throughout the study period: 40 studies (87%) were published after 2010, whereas only 6 
between 2000 and 2010. Due to the heterogeneous nature of the reviewed studies, a 
synthesis of the results was not conducted. A majority of the studies (57%) were conducted 
in Europe. 
The most used single value instrument was the EQ-5D, used in 36 studies. SF-6D was used in 
10 studies and 15D in two (Studies I and III of this thesis). Time trade-off (TTO) was used in 
two studies and standard gamble (SG) in one. Other health utility index instruments such as 
HUI, QWB, Rosser-Kind, and AQoL were not found. In most of the studies, cancer-specific 
HRQoL instruments were also used, namely the EORTC QLQ-C30 in 15 studies and Functional 
Assessment of Cancer Therapy – Cancer (FACT-C) in 10 studies.  
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All the economic evaluations included were cost−utility analyses (CUA) and one also included 
monetary valuation of the health gain (cost−benefit analysis, CBA). The intervention assessed 
was in three cases a medicine (bevacizumab, oxaliplatin-based chemotherapy) and in two 
cases a surgical procedure and in one study a telephone-based follow-up programme. The 
EQ-5D was used in all the evaluations considering medicines and the SF-6D in the surgery 
evaluations.  
In clinical trials that were included in the review, the EQ-5D was the only single index value 
instrument used. It was usually combined with the EORTC QLQ-C30 or FACT-C. The 
intervention studied was in 9 cases out of 16 a surgical procedure and in 7 cases 
chemotherapy or a biological therapy. All the clinical trial studies were run in Europe except 
one in the USA. The patient population in the surgery trials were mainly newly diagnosed 
whereas in the drug trials they were metastatic stage patients. In the observational studies 
included, the study design was usually cross-sectional and patients’ disease stages varied. 
Patient samples varied from 75 to 6713. Six studies were conducted in Asia.   
Mapping is a technique aimed at converting the scores of disease-specific HRQoL measures 
to single index value, which could then be used in economic evaluations. Of the seven 
mapping studies reviewed, in four a model to map FACT-C/G values to SF-6D was built and 
in two of those also to EQ-5D. In two studies EORTC QLQ-C30 values were mapped to EQ-5D. 
In three studies the reliability and validity of the index value instrument (EQ-5D or SF-6D) 
was assessed among colorectal patients.  
 
Conclusions 
There is no gold standard measure but different instruments are used widely. The EQ-5D 
seems to be the standard single index value instrument used when studying medicines and 
SF-6D is more often used in the operative settings. In clinical trials and observational studies, 
a generic instrument is usually combined with a cancer-specific instrument such as EORTC 
QLQ-C30 or FACT-C. 
 
 
 26
 
Ta
bl
e 
2.
  
Su
m
m
ar
y 
of
 H
RQ
oL
 p
ub
lic
at
io
ns
 in
clu
de
d 
 Fi
rs
t a
ut
ho
r, 
re
fe
re
nc
e 
Co
un
tr
y 
N 
St
ud
y 
se
tti
ng
 
HR
Qo
L i
ns
tr
um
en
ts
 u
se
d 
St
ud
y 
po
pu
la
tio
n 
Ec
on
om
ic 
ev
al
ua
tio
n 
 
 
 
 
 
 
Ca
rt
er
, 2
01
4 
[3
1]
 
Au
st
ra
lia
 
40
1 
CU
A1
 o
f b
ev
ac
izu
m
ab
 p
lu
s c
ap
ec
ita
bi
ne
 
EQ
-5
D,
 U
BQ
-C
2  
m
CR
C 
1s
t l
in
e 
 
Ca
sh
in
, 2
01
8 
[3
2]
 
Sw
ed
en
 
48
 
CU
A 
of
 cy
to
re
du
ct
iv
e 
su
rg
er
y 
w
ith
 in
tr
ap
er
ito
ne
al
 
ch
em
ot
he
ra
py
 v
s s
ys
te
m
ic 
ch
em
ot
he
ra
py
 
SF
-3
6,
 S
F-
6D
, E
OR
TC
 Q
LQ
-C
30
 
m
CR
C 
(p
er
ito
ne
al
 m
et
as
ta
se
s)
 
 
Fr
an
ke
n,
 2
01
7 
[3
3]
 
Ne
th
er
la
nd
s 
49
2 
CU
A 
of
 ca
pe
cit
ab
in
e 
an
d 
be
va
ciz
um
ab
 m
ai
nt
en
an
ce
 
EQ
-5
D 
m
CR
C 
+2
nd
 li
ne
 
 
Go
rd
on
, 2
01
5 
[3
4]
 
Au
st
ra
lia
 
41
0 
CU
A 
of
 te
le
ph
on
e 
su
pp
or
t, 
RC
T 
SF
-6
D 
CR
C,
 v
ar
io
us
 st
ag
es
 
 
M
ich
al
op
ou
lo
s, 
20
13
[3
5]
 
Gr
ee
ce
 
92
 
CU
A 
of
 la
pa
ro
sc
op
ic 
vs
 o
pe
n 
su
rg
er
y 
EQ
-5
D,
 S
F-
36
, E
OR
TC
 Q
LQ
-C
30
 
Lo
ca
l C
RC
 
 
Ro
bl
es
-Z
ur
ita
, 2
01
8 
[3
6]
 
M
ul
ti-
co
un
tr
y 
60
88
 
CU
A/
CB
A3
 o
f t
w
o 
di
ffe
re
nt
 o
xa
lip
la
tin
 co
m
bi
na
tio
n 
EQ
-5
D 
Lo
ca
l C
RC
, a
dj
uv
an
t t
he
ra
py
 
 
 
 
 
 
 
 
Cl
in
ica
l t
ria
ls 
 
 
 
 
 
 
An
to
nu
zz
o,
 2
01
5 
[3
7]
 
Ita
ly
 
19
7 
RC
T4
: O
pe
n 
la
be
l b
ev
ac
izu
m
ab
 p
lu
s X
EL
OX
 
EQ
-5
D,
  
Lo
ca
lly
 a
dv
an
ce
d 
or
 m
CR
C,
 1
st
 li
ne
 
 
Au
ge
st
ad
, 2
00
8 
[3
8]
 
No
rw
ay
 
11
0 
RC
T:
 C
om
pa
re
 fo
llo
w
-u
p 
st
ra
te
gy
 a
fte
r p
rim
ar
y 
su
rg
er
y:
 
ho
sp
ita
l v
s p
rim
ar
y 
ca
re
 u
nt
il 
24
 m
on
th
s 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
CR
C 
di
ffe
re
nt
 st
ag
es
 
 
Be
nn
et
t, 
20
11
 [3
9]
 
M
ul
ti-
co
un
tr
y 
12
53
 
Co
m
bi
ne
d 
an
al
ys
is 
of
 2
 p
ha
se
 II
I p
an
itu
m
um
ab
 p
lu
s 
ch
em
ot
he
ra
py
 R
CT
s 
EQ
-5
D 
m
CR
C 
1−
2 
lin
e 
 
Br
ig
ic,
 2
01
7 
[4
0]
 
UK
 
91
 
Ca
se
 co
nt
ro
l s
tu
dy
: H
RQ
oL
 2
−4
 y
ea
rs
 a
fte
r c
ol
ec
to
m
y 
vs
 
he
al
th
y 
co
nt
ro
ls 
EQ
-5
D 
Co
lo
n 
ca
nc
er
, s
ta
ge
 I−
III
 
 
Di
ou
f, 
20
14
 [4
1]
 
M
ul
ti-
co
un
tr
y 
62
0 
Ph
as
e 
III
 se
co
nd
ar
y 
an
al
ys
is 
of
 F
O
LF
OX
 R
CT
: p
ro
gn
os
tic
 
va
lu
e 
of
 H
RQ
oL
 fo
r O
S5
 
EQ
-5
D 
 
m
CR
C 
1s
t l
in
e 
 
Do
or
ne
bo
sc
h,
 2
00
7 
[4
2]
 
Ne
th
er
la
nd
s 
62
 
RC
T:
 T
EM
 v
s T
M
E6
 v
s h
ea
lth
y 
co
nt
ro
ls 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
Re
ct
al
 ca
nc
er
: p
rim
ar
y 
su
rg
er
y 
 
Ga
da
n,
 2
01
7 
[4
3]
 
Sw
ed
en
 
98
 
Lo
ng
-te
rm
 fo
llo
w
-u
p 
(1
2 
y)
 a
fte
r r
ec
ta
l r
es
ec
tio
n:
 
te
m
po
ra
ry
 st
om
a 
vs
 n
o 
st
om
a 
 
EQ
-5
D 
Re
ct
al
 ca
nc
er
: r
es
ec
tio
n 
 
 
Ha
ap
am
äk
i, 
20
11
 [4
4]
 
Sw
ed
en
 
19
 
Fo
llo
w
-u
p 
af
te
r e
xt
en
de
d 
ab
do
m
in
op
er
in
ea
l e
xc
isi
on
  
EQ
-5
D 
Pr
im
ar
y o
r r
ec
ur
re
nt
 re
ct
al
 o
r a
na
l 
ca
nc
er
 
 
1  C
os
t-u
til
ity
 a
na
ly
sis
 
2  U
til
ity
 B
as
ed
 Q
ua
lit
y 
of
 Li
fe
 Q
ue
st
io
nn
ai
re
 −
 C
an
ce
r. 
 
3  C
os
t-b
en
ef
it 
an
al
ys
is 
4  R
an
do
m
ize
d 
cli
ni
ca
l t
ria
l 
5  O
ve
ra
ll 
su
rv
iv
al
 
6  T
EM
 –
 tr
an
sa
na
l e
nd
os
co
pi
c m
icr
os
ur
ge
ry
, T
M
E 
– 
to
ta
l m
es
or
ec
ta
l e
xc
isi
on
. 
 27
 
 
Ja
ns
on
, 2
00
7 
[4
5]
 
Sw
ed
en
 
28
5 
RC
T:
 F
ol
lo
w
-u
p 
af
te
r l
ap
ar
os
co
pi
c v
s o
pe
n 
su
rg
er
y 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
Co
lo
n 
ca
nc
er
, s
ta
ge
 I−
III
 
 
Ko
ed
am
, 2
01
7 
[4
6]
 
Ne
th
er
la
nd
s 
30
 
Fo
llo
w
-u
p 
af
te
r t
ra
ns
an
al
 to
ta
l m
es
or
ec
ta
l e
xc
isi
on
 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
Re
ct
al
 ca
nc
er
, p
rim
ar
y 
tr
ea
tm
en
ts
 
(I−
IV
) 
 
Od
om
, 2
01
1 
[4
7]
 
M
ul
ti-
co
un
tr
y 
46
3 
Ph
as
e 
III
 R
CT
:  
pa
ni
tu
m
um
ab
 v
s b
es
t s
up
po
rt
iv
e 
ca
re
  
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
Ch
em
ot
he
ra
py
-re
fra
ct
or
y 
m
CR
C 
+3
 li
ne
 
 
Sh
ar
m
a,
 2
00
7 
[4
8]
 
UK
 
10
4 
Fo
llo
w
-u
p 
af
te
r e
le
ct
iv
e 
re
se
ct
io
n 
EQ
-5
D,
 F
AC
T-
C7
 
CR
C,
 p
rim
ar
y 
tr
ea
tm
en
t 
 
Si
en
a,
 2
00
7 
[4
9]
 
M
ul
ti-
co
un
tr
y 
46
3 
Ph
as
e 
III
 R
CT
 se
co
nd
ar
y 
an
al
ys
is:
 A
ss
oc
ia
tio
n 
of
 P
FS
8  w
ith
 
HR
Qo
L a
nd
 O
S,
 p
an
itu
m
um
ab
 v
s b
es
t s
up
po
rt
iv
e 
ca
re
 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
m
CR
C 
Th
al
er
, 2
01
2 
[5
0]
 
Au
st
ria
 
15
4 
Ph
as
e 
II 
RC
T:
 s
ki
n 
to
xic
ity
 a
nd
 Q
oL
, p
an
itu
m
um
ab
 p
lu
s 
FO
LF
IR
I  
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
m
CR
C 
1s
t l
in
e 
 
W
ar
d,
 2
01
4 
[5
1]
 
US
A 
45
 
Su
b 
an
al
ys
is 
of
 p
ha
se
 II
 c
ap
ec
ita
bi
ne
 a
nd
 b
ev
ac
izu
m
ab
: 
fo
llo
w
-u
p 
of
 H
RQ
oL
 b
et
w
ee
n 
pa
tie
nt
s w
ith
 E
CO
G 
1/
29
 
EQ
-5
D,
 F
AC
T-
C 
Ge
ria
tr
ic 
m
CR
C 
 
Ve
rs
ev
el
d,
 2
01
6 
[5
2]
 
Ne
th
er
la
nd
s 
24
 
Fo
llo
w
-u
p 
af
te
r t
ra
ns
an
al
 m
in
im
al
ly
 in
va
siv
e 
su
rg
er
y 
EQ
-5
D,
 F
IQ
L1
0  
Lo
ca
l (
T0
−I
) r
ec
ta
l c
an
ce
r 
Ob
se
rv
at
io
na
l s
tu
di
es
 
 
 
 
 
 
 
Do
w
ni
ng
, 2
01
9 
[5
3]
 
UK
 
67
13
 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y:
 H
RQ
oL
 a
fte
r c
ur
at
iv
e 
tr
ea
tm
en
t  
EQ
-5
D-
5L
, F
AC
T-
C 
Re
ct
al
 ca
nc
er
, p
rim
ar
y 
tr
ea
tm
en
ts
 
(I−
IV
) 
 
Es
co
ba
r, 
20
15
 [5
4]
 
Sp
ai
n 
19
3 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y 
of
 3
-y
ea
r c
an
ce
r s
ur
vi
vo
rs
 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
Br
ea
st
, 
co
lo
re
ct
al
 
or
 
pr
os
ta
te
 
ca
nc
er
  
 
Fä
rk
ki
lä
, 2
01
3 
[5
5]
 
Fi
nl
an
d 
50
8 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y 
of
 H
RQ
oL
 
EQ
-5
D,
 1
5D
, E
OR
TC
 Q
LQ
-C
30
 
CR
C,
 v
ar
io
us
 st
ag
es
 
 
Fä
rk
ki
lä
, 2
01
4 
[5
6]
 
Fi
nl
an
d 
11
4 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y 
of
 H
RQ
oL
 
EQ
-5
D,
 1
5D
, E
OR
TC
 Q
LQ
-C
30
 
En
d-
st
ag
e 
m
CR
C 
 
Ho
rn
br
oo
k,
 2
01
1 
[5
7]
 
US
A 
64
0 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y,
 a
na
ly
sis
 o
f H
RQ
oL
 d
et
er
m
in
an
ts
 
SF
-6
D,
 C
OH
-Q
OL
-O
st
om
y1
1  
>5
-y
ea
r s
ur
vi
vo
rs
 o
f C
RC
 
 
Hu
an
g,
 2
01
8 
[5
8]
 
Ch
in
a 
30
0 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y,
 a
na
ly
sis
 o
f H
RQ
oL
 d
et
er
m
in
an
ts
 
EQ
-5
D-
5L
 
CR
C,
 p
rim
ar
y 
tr
ea
tm
en
ts
, 
st
ag
e 
va
rie
s 
 
Ki
m
, 2
01
2 
[5
9]
 
Ko
re
a 
13
3 
Cr
os
s-
se
ct
io
na
l 
su
rv
ey
, 
as
se
ss
m
en
t 
of
 
va
lid
ity
 
an
d 
re
lia
bi
lit
y 
 
EQ
-5
D,
 S
F-
36
, E
OR
TC
 Q
LQ
-C
30
 
CR
C,
 v
ar
io
us
 st
ag
es
 
 
M
ar
ce
llu
si,
 2
01
5 
[6
0]
 
Ita
ly
 
46
5 
Cr
os
s-
se
ct
io
na
l 
an
al
ys
is 
of
 H
PV
-in
du
ce
d 
ca
nc
er
 H
RQ
oL
 
lo
ss
 
EQ
-5
D,
 ti
m
e 
tr
ad
e-
of
f 
HP
V-
re
la
te
d 
ca
nc
er
s 
 
Se
tia
w
an
, 2
01
8 
[6
1]
 
In
do
ne
sia
 
11
6 
Cr
os
s-
se
ct
io
na
l 
an
al
ys
is 
of
 H
PV
-in
du
ce
d 
ca
nc
er
 H
RQ
oL
 
lo
ss
 
EQ
-5
D 
HP
V-
re
la
te
d 
ca
nc
er
s 
 
7  F
un
ct
io
na
l A
ss
es
sm
en
t o
f C
an
ce
r T
he
ra
py
 −
 C
ol
or
ec
ta
l c
an
ce
r. 
8  P
ro
gr
es
sio
n 
fre
e 
su
rv
iv
al
 
9  E
as
te
rn
 C
oo
pe
ra
tiv
e 
On
co
lo
gy
 G
ro
up
 (E
CO
G)
 P
er
fo
rm
an
ce
 st
at
us
. 
10
 F
ae
ca
l I
nc
on
tin
en
ce
 Q
ua
lit
y 
of
 Li
fe
. 
11
 C
ity
 o
f H
op
e 
Q
ua
lit
y 
of
 Li
fe
-O
st
om
y.
 
 28
 
 
Sh
iro
iw
a,
 2
00
9 
[6
2]
 
Ja
pa
n 
15
00
 
Di
re
ct
 v
al
ua
tio
n 
of
 2
5 
CR
C 
he
al
th
 st
at
es
   
TT
O,
 S
G 
Ge
ne
ra
l p
op
ul
at
io
n 
 
St
ei
n,
 2
01
4 
[6
3]
 
M
ul
ti-
co
un
tr
y 
75
 
Cr
os
s-
se
ct
io
na
l s
tu
dy
, p
re
- v
s p
os
t-p
ro
gr
es
sio
n 
EQ
-5
D 
m
CR
C 
2n
d 
lin
e+
 
 
W
on
g,
 2
01
3 
[6
4]
 
Ho
ng
ko
ng
 
16
0 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y,
 a
na
ly
sis
 o
f H
RQ
oL
 d
et
er
m
in
an
ts
 
SF
-6
D,
 F
AC
T-
C 
CR
C,
 v
ar
io
us
 st
ag
es
 
 
W
on
g,
 2
01
4 
[6
5]
 
Ho
ng
ko
ng
 
16
0 
Cr
os
s-
se
ct
io
na
l s
tu
dy
, c
om
pa
ris
on
 o
f d
ire
ct
 a
nd
 m
ap
pe
d 
SF
-6
D 
SF
-6
D,
 S
F-
12
, F
AC
T-
C 
CR
C,
 v
ar
io
us
 st
ag
es
 
 
W
on
g,
 2
01
8 
[6
6]
 
Ch
in
a 
53
3 
Cr
os
s-
se
ct
io
na
l s
ur
ve
y,
 H
RQ
oL
 im
pa
ct
 o
n 
he
al
th
 s
er
vi
ce
 
us
e 
SF
-6
D,
 F
AC
T-
C 
CR
C,
 v
ar
io
us
 st
ag
es
 
M
ap
pi
ng
 a
nd
 m
et
ho
do
lo
gi
c s
tu
di
es
 
 
 
 
 
 
Co
lw
el
l, 
20
10
 [6
7]
 
US
A 
39
1 
Ev
al
ua
tio
n 
of
 r
el
ia
bi
lit
y,
 v
al
id
ity
 a
nd
 r
es
po
ns
iv
en
es
s 
of
 
FC
SI
-9
  
EQ
-5
D,
 F
CS
I-9
12
 
m
CR
C 
 
Ki
m
, 2
01
4 
[6
8]
 
Ko
re
a 
22
11
 
M
ap
pi
ng
 S
F-
36
 to
 E
Q
-5
D 
EQ
-5
D 
Va
rio
us
 ca
nc
er
 ty
pe
s 
 
Le
e,
 2
01
3 
[6
9]
 
Ca
na
da
 
19
1 
Va
lid
at
io
n 
of
 S
F-
36
 in
 p
os
to
pe
ra
tiv
e 
re
co
ve
ry
 
SF
-6
D,
 S
F-
36
 
CR
C,
 p
rim
ar
y 
tr
ea
tm
en
ts
, 
st
ag
e 
I−
IV
 
 
M
ar
rio
tt
, 2
01
7 
[7
0]
 
M
ul
ti-
co
un
tr
y 
52
9 
M
ap
pi
ng
 E
OR
TC
 Q
LQ
-C
30
 to
 E
Q
-5
D 
EQ
-5
D,
 E
OR
TC
 Q
LQ
-C
30
 
1L
 
m
RC
 
liv
er
-o
nl
y 
or
 
liv
er
 
do
m
in
an
t  
 
Te
ck
le
, 2
01
3 
[7
1]
 
Ca
na
da
 
36
7 
M
ap
pi
ng
 F
AC
T-
G 
to
 E
Q
-5
D 
an
d 
SF
-6
D 
EQ
-5
D 
 
CR
C,
 b
re
as
t, 
lu
ng
 ca
nc
er
 
 
Te
ck
le
, 2
01
1 
[7
2]
 
Ca
na
da
 
36
7 
M
ap
pi
ng
 F
AC
T-
G 
to
 E
Q
-5
D 
an
d 
SF
-6
D 
EQ
-5
D 
 
CR
C,
 b
re
as
t, 
lu
ng
 ca
nc
er
 
 
W
on
g,
 2
01
2 
[7
3]
 
Ch
in
a 
53
7 
M
ap
pi
ng
 F
AC
T-
G 
to
 S
F-
6D
 
SF
-6
D 
 
CR
C 
di
ffe
re
nt
 st
ag
es
 
 
W
on
g,
 2
01
4 
[7
4]
 
Ch
in
a 
33
3 
Re
sp
on
siv
en
es
s o
f d
ire
ct
 a
nd
 m
ap
pe
d 
SF
-6
D 
va
lu
es
 
SF
-6
D,
 S
F-
12
, F
AC
T-
C 
CR
C 
di
ffe
re
nt
 st
ag
es
 
 
Ya
ng
, 2
01
4 
[7
5]
 
Ch
in
a 
55
3 
M
ap
pi
ng
 F
AC
T-
C 
to
 S
F-
6D
 
SF
-6
D,
 F
AC
T-
C 
 
CR
C 
di
ffe
re
nt
 st
ag
es
 
 
12
 F
AC
T 
Co
lo
re
ct
al
 C
an
ce
r S
ym
pt
om
 In
de
x.
 
 29 
2.3 COST OF COLORECTAL CANCER  
Assessments of colorectal cancer costs are important both to understand the burden of 
disease on society and to make decisions between different health-care programmes and 
treatment options to prevent, diagnose and treat the disease.  
There is a lot of heterogeneity in the cost studies in health care. One underlying reason is 
that the cost data are mainly created and used for billing and the availability and structure 
of the data are defined by the health-care funding structure [76].  An alternative for registry-
based data collection is so called ‘micro costing’, which is not without challenges and is  
laborious [77].  
Costing principles 
Costing includes two elements: measurement of the quantities of used resources and their 
valuation (assigning of price or unit cost to the resources). Usually market prices are used for 
valuation, but theoretically the right price would be the opportunity costs of the used 
resource. The main categories of costs associated with health care programmes are: costs 
arising from resource use within the health sector (direct costs), resource use by patients 
and their families (informal care), resource use by other sectors (direct non-health-care 
costs), and productivity losses due to inability to work. [11] 
Direct health-care costs 
Direct health-care costs include: intervention costs (practitioners’ fees, diagnostic costs, 
therapy costs etc); service costs (facilities and equipment, hospitalization and clinic fees, and 
ancillary services); and overheads. The valuation of these is rather straightforward as the 
market prices are mainly easily available and resource utilization well documented for billing 
purposes. 
Direct non-health-care costs  
Direct non-health-care costs are a consequence of the consumption of resources outside the 
health sector, such as transportation to care, social services, household expenditures and 
informal care.  
Informal care is defined as care given by family or friends. Quantification and valuation of 
informal care is often laborious as the amount of care received is not systematically 
documented and there is no direct market substitute for pricing. Informal care is rarely 
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included in economic evaluations, but its share might be substantial, especially in chronic 
diseases [78]. Informal care is usually unpaid or compensated only partially by government 
benefits that do not reflect the true value of the service. The alternative methods that could 
be used for valuation are: the proxy good method; the opportunity cost method; the 
contingent valuation method; conjoint measurement and valuation of health effects in terms 
of HRQoL [79]. In the well-being approach, the level of compensation should enable the well-
being of the carer  to be maintained at the same level as without care [80]. 
Productivity costs 
Productivity cost or productivity losses arise due to morbidity and mortality causing patient’s 
or carer’s inability to work. Value of lost productive time is borne by the individual, family, 
society, or the employer. The valuation of productivity losses and to what extent they should 
be included in economic evaluations are controversial. It is also contentious whether 
productivity changes should be considered as costs or consequences [11].  
The most used evaluation method for productivity losses is the human capital approach 
where gross earnings including employer costs and benefits is used. This method has been 
criticized for overestimating the true cost to society as in many cases short-term absences 
are compensated by other workers. In a case of long-term absence, the employer likely hires 
someone to replace the absent worker. An alternative method is the so-called friction cost 
method, where the cost is based on the expenses to the employer of replacing the employee 
and restoring the production to the initial level [81, 82].  
Even when being physically at work, patients with a severe disease like cancer might not be 
able to fully perform their duties and are more likely to make mistakes. This so called 
‘presenteeism’ is defined as a situation where an employee is not fully functioning in the 
workplace because of an illness, injury or other condition and this might accrue substantial 
productivity costs [83].  
Intangible costs 
In early cost-of-illness literature, the willingness to pay to avoid suffering, such as pain and 
anxiety, was defined as an intangible cost [84]. In economic evaluation where health gains 
and losses are quantified, intangible costs should not be included to avoid double counting.  
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Perspective for the analysis 
The costs included in the analysis vary based on the selected perspective of the study. The 
perspective defines the budget holder who bears the consequences of the used resources. 
The most commonly used perspectives are described in the table below (Table 3) [85]. 
Societal perspective is the broadest, including all resource use. 
Table 3.  The types of costs included in the analysis with a different perspective 
Society Health system Payer Patient 
All costs incurred as a 
whole irrespective of 
the payer 
All costs of health-care 
providers 
- Health-care 
professional salaries 
- Cost of medication 
- Equipment 
- Fixed assets 
Costs borne by payer, 
e.g. municipality, 
insurance, sick-fund 
 
All costs paid by a 
patient when seeking 
care: 
- Out-of-pocket 
payments (fees and 
co-pays) 
- Costs of transport 
- Costs of taking time 
off work 
 
Costs in CRC literature search  
The objective of this literature search was to understand what type of cost studies are 
published, and to summarize the costs related to colorectal cancer care across the disease 
states.  
Methods 
We used the PubMed electronic database to identify articles about costs and CRC that were 
published between January 2000 and June 2019 in the English language. We used the 
Medical subject headings (MeSH) search strategy with the subject term “colorectal 
neoplasms” combined with MeSH major subject terms “costs and cost analysis”. This yielded 
365 studies of which 177 were review articles, letters, editorials or congress abstracts and 
thus excluded. We focused only on CRC care and thus prevention and screening studies were 
not included. Also, studies focusing on assessing the cost implication of a specific treatment 
option or its cost-effectiveness were excluded. Using these criteria, 28 papers for closer 
review were selected (Figure 6).  
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Figure 6.  Flow diagram of the literature search process of CRC cost articles. 
Results of the review 
A majority of the literature of CRC-related costs was focused on screening or analysing the 
cost-effectiveness of a specific treatment. In our review we focused on patient level cost 
analysis of the disease states (Table 4). Of 28 studies, 12 were conducted in the USA where 
cost data are easily available from health insurance registries. All US studies were conducted 
from the health insurance perspective. Seven studies utilized the Surveillance, Epidemiology, 
and End Results database which is linked to Medicare. This health insurance programme is 
for people who are older than 65. In studies utilizing US health insurance data, the sample 
size is big, ranging from 598 to 144,130 patients. Twelve studies were conducted in Europe. 
In these studies, the perspective varied from patient to carers and to society. Four studies 
were carried out in Asia (China, Malaysia and Jordan).  
The most used study setting was the incidence-based observational cohort study after CRC 
diagnosis (16 studies). The most common follow-up time was one year after diagnosis but it 
varied from 90 days to lifetime. Six studies were cross-sectional prevalence-based studies. In 
roughly half of the studies costs were compared to age-matched non-cancer controls, 
whereas the rest assessed the total costs. Eight studies examined costs to patients and carers 
through a survey and four of them also assessed the productivity costs due to sick leave and 
early retirement.  
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Conclusions 
The type of the cost studies in CRC is determined mostly by the data available. Health 
insurance data are easily available especially in the USA and this allows longitudinal costs to 
be assessed after diagnosis and in the later phases of the disease. In European studies the 
perspective of the analysis is usually wider than just direct health-care costs to the payer. 
Patients’ perspective, indirect costs or productivity cost are not widely studied and the 
methodologies used vary.    
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2.4 ECONOMIC EVALUATION 
Economic evaluation is needed to systematically identify, measure and value the inputs and 
outputs of alternative policies and interventions that should improve health. Each decision 
to choose one intervention over another will have effects both on health, but also on health-
care resources. Health-care resources are limited and the true cost of used resources is the 
benefit from the best alternative choice that was lost (opportunity cost). The purpose of 
economic evaluations is to help make informed decisions of resource use to maximize health 
benefits. The evidence of alternative courses of action, which is mainly available from clinical 
trials, provides the key data for this Economic evaluation is a complement to clinical 
evaluation as it provides a framework with which to combine clinical evidence of alternative 
interventions with cost data to maximize value to society [11, 114, 115].  
Evaluation types 
The type of the study should be selected based on what is evaluated and what is the 
valuation of the consequences (Table 5). The four different types of evaluation studies are: 
cost analysis; cost-effectiveness analysis; cost−utility analysis, and cost−benefit analysis.  
Table 5.  Economic evaluation types (adapted from Drummond et al. 2015 [11])  
Type of evaluation Measurement/ 
valuation of costs 
Identification of 
consequences 
Measurement/valuation of 
consequences 
Cost analysis or cost 
minimization analysis 
Money None or same between 
alternatives 
None 
Cost-effectiveness 
analysis 
Money Same single effect for both 
alternatives but achieved to 
different degrees 
Natural units  
(e.g. life-years gained, 
progression-free survival, blood
pressure) 
Cost-utility analysis Money Single or multiple effects, not 
necessarily same in both 
alternatives 
QALYs (healthy years) 
Cost-benefit analysis Money Single or multiple effects, not 
necessarily same in both 
alternatives 
Money 
 
Cost analysis is the simplest analysis and should be used if the outcome is shown to be similar 
in the compared alternatives. Cost-effectiveness analysis could be the right method, when 
resource allocation decisions are made within one therapeutic area, e.g. progression-free 
survival (PFS) in certain cancer types. Cost-utility analysis incorporates the quantity and 
quality of incremental survival. This is needed when decisions around resource allocation are 
made between different disease areas in health care, and are thus usually based on the 
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payer’s requirement for health technology assessment. In cost−benefit analysis the health 
gain is valued in money as well. A positive decision should be taken if the monetary value of 
benefits is higher than that of costs. 
 
Decision-analytic modelling 
At the time when new treatment options become available, i.e. after marketing 
authorization approval, a limited amount of evidence is available. Usually the evidence is 
from randomized clinical trials (RCTs) where the patient population is highly selected, 
treatment procedure does not match with local procedures, follow-up period is short, or 
comparators used might not be relevant. Also, in the RCTs the focus is on efficacy – how the 
treatment works under ideal conditions with selected patients – rather than effectiveness – 
how the treatment works in everyday clinical practice. Hence, RCTs seldom offer sufficient 
basis for economic evaluation and decision-making. Decision-analytic modelling provides a 
decision-making framework under conditions of uncertainty and it allows us to: 
- Combine results from different studies 
- Quantify and manage uncertainty 
- Link intermediate clinical endpoints to final outcomes 
- Synthetize head-to-head comparisons where relevant trials do not exist 
- Extrapolate beyond the results of trial 
- Localize results into different clinical practice 
In practice, a health economic model defines statistical relationships between disease states 
and describes the range of possible disease prognoses and the impact of alternative 
treatment options. Two commonly used models are decision trees and state transition 
models [116].  
 A typical cancer model structure is presented in Figure 7. Each circle corresponds to a 
disease state associated with certain costs and HRQoL. Arrows present the possible 
transitions from one health state to another. Each arrow is associated with a probability. 
When comparing different treatment options, utility values and costs in each state differ as 
do the probabilities of moving between states. This allows the calculation of incremental 
costs and effectiveness between the alternatives.  
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Figure 7. Example of health economic model structure used in cancer. 
In cancer, the primary outcome measures for the economic evaluation are usually quality-
adjusted life-years (QALYs) gained, disease-free survival and total survival. From this, the 
incremental cost-effectiveness ratios (ICER) can be derived by dividing the incremental costs 
of treatment A compared to treatment B by the incremental effectiveness (e.g. QALYs 
gained).  
Incremental cost-effectiveness ratio (ICER)  = ∆Cost
∆Effectiveness
= Cost A  - Costs B
Effectiveness A - Effectiveness B
 
Incremental analysis of costs and health effects is often presented in a cost-effectiveness 
plane (Figure 8), where the horizontal axis represents the difference in health (usually QALY) 
and the vertical axis cost the difference between the compared alternatives. 
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Figure 8.  Cost-effectiveness plane. 
Most of the interventions analysed end up in the upper-right corner: more health with more 
costs. Then it is not logically clear which alternative should be selected. Therefore, the ICER 
between the alternatives must be calculated and the maximum ICER threshold for an 
alternative to be considered cost-effective and acceptable be decided. This threshold 
represents society’s maximum willingness to pay for a unit of effectiveness, e.g. for a QALY 
gained, and this varies between countries and diseases. In Finland, the ICER threshold is not 
defined. The World Health Organization (WHO) recommends a threshold range of 1−3 times 
the gross domestic product (GDP) per capita. In the case of the upper-left and bottom-right 
corner the decision is clear: one alternative dominates over the other, i.e. is ‘better’ both in 
terms of effectiveness and costs. 
Time horizon of the analysis 
In economic evaluations the time horizon is the duration over which health effects and costs 
are calculated. The time horizon should be the period in which the cost and health 
consequences might differ between the compared interventions. In the case of cancer, the 
time horizon is usually lifetime. [117] 
Discounting 
In many cases the costs and consequences of interventions occur at different times. Benefits 
received today are valued more than those in the future. The reason for this is a 
phenomenon called ‘time preference’. To take this into account in economic evaluation, 
future health consequences and costs should be discounted [11]. The used discount rate 
might have a substantial impact on the outcomes of economic evaluations. The controversies 
around discounting are mainly about the discount rate, should the same rate be applied both 
to costs and health effects and whether the rate should be constant over time. In most 
countries, the discount rates are equal for costs and effects and vary between 1.5 and 
5%[118].  
Choice of the comparator 
Economic evaluation always involves a comparative analysis of at least two interventions. 
The choice of comparator is critical as it defines against which alternative the incremental 
health benefits and costs should be evaluated. The comparator should be the second best 
alternative and it was thus usually the standard of care used before the new option became 
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available. Alternative comparators to be considered might be the least costly option and the 
‘do nothing’ scenario [119, 120].  
Sensitivity analysis to manage uncertainty  
One of the benefits of the systematic decision framework that economic evaluation offers is 
that it helps to handle and manage the uncertainty. All analyses contain uncertainty, which 
may arise from the random variability between patients (stochastic uncertainty, first-order 
uncertainty), the uncertainty in estimation of the parameters (second-order uncertainty), 
heterogeneity between patients, and from the structural uncertainty of the decision model 
[121].   
There are many options for conducting a sensitivity analysis. The decision on what kind of 
sensitivity analysis to use should be made based on what type of uncertainty should be 
managed. In one-way sensitivity analysis each variable is varied at a time, other things equal, 
to assess the impact on end-result. In multi-way analysis several variables are varied at the 
same time. In threshold analysis one parameter is varied until the tipping point where the 
outcome measure reaches the predefined threshold (e.g. ICER threshold). Probabilistic 
sensitivity analysis is the most sophisticated approach to analysing stochastic uncertainty. 
Here probability distributions of key input parameters are used to produce a distribution of 
outputs [121].  
It has been assessed that in the economic evaluations the parameter uncertainty associated 
with HRQoL estimates had the biggest impact on results, followed by cost estimates and use 
of different discount rates [122].
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3 AIMS OF THE STUDY 
Cancer is becoming more and more common as people live longer and new treatment 
options improve survival rates. However, there is still a substantial unmet need and thus a 
remarkable share of research and development investments are focused on developing new 
cancer therapies. Patients’ HRQoL is important when making treatment choice decisions, 
especially in cancer where some therapies might offer limited survival benefit with even a 
negative impact on HRQoL due to adverse effects. New drug discoveries are expensive and 
thus it becomes even more important in the future to have a rigid health technology 
assessment in place to allocate scarce resources optimally. The main aim of this series of 
studies was to evaluate HRQoL and costs associated with CRC and to generate crucial real-
world data to be used in cost-effectiveness analyses. In addition, BC, PC, and CRC patients’ 
financial burden and its HRQoL implications was explored and late-stage BC, PC and CRC 
patients’ HRQoL assessed.  
The specific aims were: 
1. To assess the HRQoL among various disease states of CRC in a real-world setting 
using three standard instruments – 15D, EQ-5D and EORTC QLQ-C30 − and to 
explore clinical and demographic factors associated with HRQoL in CRC (Study I). 
 
2. To explore all resource use and costs, including direct health-care costs, 
productivity costs and costs of informal care, in different disease states of CRC 
(Study II). 
 
3. To evaluate end-stage breast (BC), prostate (PC) and CRC patients’ HRQoL and to 
compare three different instruments – 15D, EQ-5D and EORTC QLQ-C30 – in this 
population and explore factors related to poor HRQoL (Study III). 
 
4. To assess the direct economic burden on BC, PC and CRC patients due to out-of-
pocket (OOP) expenditure and to explore how it is associated with decreased 
HRQoL measured by the 15D. Furthermore, the factors that explain financial 
difficulties were analysed (Study IV).
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4 PATIENTS AND METHODS 
The study is based on a survey and registry study of 1978 breast, prostate and colorectal 
patients conducted in the Hospital District of Helsinki and Uusimaa (HUS) between October 
2009 and February 2011. Hospital District of Helsinki and Uusimaa covers almost 30% of the 
Finnish population.  
4.1 PATIENT ENROLMENT 
All patients aged 18 and above, diagnosed with primary or recurrent BC, PC or CRC after 2005 
in HUS were eligible for the study. Patient recruitment was designed to achieve a balanced 
sample of patients from different disease states and cancers. The goal was to include 1000 
BC patients, 500 PC patients and 500 CRC patients. The predefined disease states were: 
- Primary treatments (local disease, 0–6 months after diagnosis), 
- Rehabilitation (local disease, 6–18 months after diagnosis),  
- Remission (local disease, more than 18 months after diagnosis), 
- Metastatic disease (patients having metastases and having received oncological 
treatment) and 
- Palliative care (metastatic disease and patients receiving only non-oncological 
treatment) 
The disease states were decided based on clinical relevance and applicability in health 
economic modelling.  
Patients were identified when visiting hospital or from hospital patient records based on the 
time of diagnosis. Patients were recruited by mailing a consent letter and a questionnaire 
(Appendix 1). Patients in primary treatments and in a palliative care state were recruited by 
a research nurse when visiting the hospital or the Terhokoti hospice. Patients who did not 
respond to the original invitation received one reminder. Patients returned the consent form 
and the questionnaire to the clinic or via mail in a prepaid envelope. 
4.2 STUDY POPULATION 
The inclusion criteria were met/fulfilled by 1978 patients and these were included in the 
analysis. Of the population, 840 had BC, 630 PC and 508 CRC (Table 6). Patients’ age ranged 
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from 26 to 96 with a mean of 66 years, and the time from diagnosis varied from 1 week to 
24 years with the mean time being 3 years. 
The data set is extensive and unique and it is utilized in five other doctoral thesis studies. 
Table 6 shows which part of the data set is utilized in each article of this thesis.  
Table 6.  Characteristics of the study population, n (%) 
 
 Breast Prostate Colorectal Total 
Respondents 840 (42) 630 (32) 508 (26) 1978 (100) 
Response rate     
Female, % 835 (99) 0 (0) 238 (47) 1073 (54) 
Age, mean (SD)  62 (11) 69 (8) 68 (11) 66 (11) 
Disease state     
Primary treatment 118 (14) 47 (7) 61 (12) 226 (11) 
Rehabilitation 150 (18) 158 (25) 79 (16) 387 (20) 
Remission 382 (45) 317 (50) 217 (43) 916 (46) 
Metastatic disease 176 (21) 89 (14) 110 (22) 375 (19) 
Palliative care 14 (2) 19 (3) 411 (8) 74 (4) 
Other background factors      
Higher education  483 (58) 308 (55) 279 (55) 1070 (57) 
White collar 431 (52) 309 (56) 251 (50) 991 (53) 
Married/cohabiting 520 (63) 457 (82) 334 (67) 1311 (70) 
Employed 325 (39) 102 (18) 115 (23) 542 (29) 
Unemployed 20 (2) 12 (2) 7 (1) 39 (2) 
Retired 454 (55) 432 (78) 365 (73) 1251 (66) 
     
 Studies I, II, n = 508   
 Study III, n = 114   
 Study IV, n = 1978   
 
4.3 MEASURING HRQOL 
The HRQoL data were collected through a broad self-administered questionnaire (Appendix 
1) utilizing the cancer-specific EORTC QLQ-C30 instrument and two generic, single index 
measures, the 15D and the EQ-5D including a visual analogue scale (VAS). For the 15D we 
used the Finnish valuation algorithm for HRQoL scores and profiles. For the EQ-5D the UK 
time trade-off (TTO) tariff was used. These instruments were selected as they are widely 
 
1 The definition of palliative care varied between studies. In Studies I, II and IV the patients who had metastatic 
disease and who were no longer receiving oncological treatments were included. In Study III the patients who 
died within the following six months after they responded to the questionnaire were also included.  
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used among cancer patients in Finland and thus allow comparison with previous and future 
results. 
The patient questionnaire also included questions about their socio-demographic situation 
and health-care resource use. This is a cross-sectional study by design, so patients answered 
the questionnaire only once. Within the five disease states the patients’ date of answering 
was not defined.  
In Study I, the CRC patients’ HRQoL measured by the 15D and EQ-5D was compared to that 
of an age-, gender- and education-standardized sample of the general Finnish population. 
The population reference values were available from the Finnish Health 2000 Health 
Examination Survey [123].  
4.4 COSTS AND RESOURCE USE 
Cost and resource data are comprehensive and they were collected from several registries 
(Table 7) and complemented by the patient survey (Appendix I). Costs were calculated for a 
six-month period based on the patient’s disease state. A six-month period was selected as it 
reflects the natural phases of the disease and therapies used.   
Table 7. Data sources used 
Cost and resource use  Data source: 
Primary care resource use Data from home municipality: Helsinki, Espoo, Vantaa 
Terhokoti, Hospice  
Patient survey (last 3 months) 
Private health-care use Patient survey (last 3 months),  
The Social Insurance Institution of Finland 
Unit costs primary and private health care National Institute for Health and Welfare, THL [124] 
Secondary care resource use and costs Helsinki University hospital patient records: Ecomed 
Outpatient medication and unit costs The Social Insurance Institution of Finland 
Rehabilitation  The Social Insurance Institution of Finland 
Travelling and costs The Social Insurance Institution of Finland 
Days absent from work Patient survey (last 3 months),  
The Social Insurance Institution of Finland 
Sick allowance The Social Insurance Institution of Finland 
Disability pension Patient survey (last 3 months),  
The Social Insurance Institution of Finland 
Informal care use Patient survey (last 3 months) 
Informal care costs Shadow price for a practical nurse [125]. 
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Health-care costs 
Resource use and costs in secondary health care by hospitals were obtained from the 
Ecomed® patient administration system (Datawell Ltd., Finland), which covers all the costs 
of treatment for individual patients given in the hospital and is categorized according to 
resource type. 
Primary health-care resource use data were extracted from patients’ home municipality. The 
data were available only from the three biggest cities: Helsinki, Espoo and Vantaa, which 
represented around 80% of the total study population. The data covered primary care 
general practioner (GP) and nurse visits, home hospice care, and primary care 
hospitalization. For the 20% of the patients for whom primary health-care data were missing, 
the missing values were imputed using propensity score matching, which allowed the 
calculation of the total costs. We used average unit costs from Helsinki, Espoo and Vantaa to 
calculate the primary care costs. Resource use and cost data were also available from the 
Terhokoti hospice. Mean unit costs for primary care visits and treatments were available 
from the National Institute for Health and Welfare, THL [124]. 
The Social Insurance Institution of Finland (KELA) provides universal social security coverage. 
It provides family benefits, health insurance, rehabilitation, basic unemployment security, 
basic social assistance, housing benefits, financial aid for students, disability benefits and 
basic pensions. Data for retail medicine reimbursements and usage, travel reimbursement, 
sick allowance, disability pensions, private health-care utilization and costs, and 
rehabilitation use and costs were available from KELA’s health insurance registry.  
Additional data on resource use and background information were gathered from patients 
with a self-administered questionnaire about: 
 Occupational health care by type of service 
 Private health-care providers 
 Cancer-related retail medicine purchases, including prescription-free products 
 Socio-economic status 
Productivity loss 
Productivity losses were estimated based on data collected from the patient survey. 
Productivity losses arise from early retirement due to cancer and sick leave due to cancer. 
For patients who are working, we also asked how they assessed their ability to work. 
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However, reduced work capacity was not included in the assessment. Regarding sick leave, 
data were also available from The Social Insurance Institution of Finland (KELA) and they 
were used to validate the days absent from work.  
The productivity loss valuation was done using the common human capital approach where 
the margin of production of the individual is valued by his or her pre-tax salary [82]. The loss 
was then calculated by multiplying the number of days absent from work by the average 
daily labour cost, including the employer’s social security payments of, on average, 38.6% in 
addition to the pre-tax salary. The pre-tax salary was established from earnings-based sick 
allowance available from KELA.  
Informal care 
In the survey, the amount of support and care given outside of the health-care system due 
to CRC was assessed based on patients’ own estimates of the last three months. Patients 
were asked to estimate the average amount of care and support from family and friends per 
week. This was then multiplied by two to calculate the total hours per a six-month period. 
We set a maximum of 16 hours per day as a limit. For imputing the missing values, we used 
the propensity score matching method. 
The proxy good method was used to value the informal care [126]. This is based on the 
shadow price of a market substitute, in this case a practical nurse. The mean pre-tax hourly 
salary for them was €13.63 in 2010 [127]. The total labour cost also includes 38.6% of social 
security payments for employers, which resulted in the final cost of €18.89 per hour, which 
was then used to multiply the hours used.  
Out-of-pocket payments 
In Study IV we assessed all the costs that are paid by the patient. These out-of-pocket (OOP) 
payments consisted of patient co-pays and fees. In Finland these are regulated by law so we 
were able to calculate the OOP payments based on total resource use per category. Patients 
incur co-pays when they use private health-care services, travel to health care, participate in 
rehabilitation, or buy reimbursed retail medicines. This cost and co-pay information was 
available from KELA.  
Fees are due to the use of public health-care services: primary and secondary health-care 
visits, hospitalization and hospice care. This information was available from the hospital and 
primary care records and was supplemented with data from the patient questionnaire. 
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Finnish law sets a maximum annual OOP ceiling for retail medicines (€672.10), travelling co-
pays (€157.25) and health-care services (€633.00). Costs related to informal care and non-
medical treatments were not included in the study.  
Incremental cost assessment 
In Study II we included only the cost caused by CRC. The incremental share of CRC costs 
regarding outpatient medication, the use of private health-care services, travelling, and days 
absent from work was estimated using two population control samples (n=1016) matched 
for age, place of residence and sex, and excluding individuals with a cancer diagnosis. The 
sample was extracted from the KELA register . The resource use in secondary health care was 
limited to CRC-related visits based on diagnosis code and clinical expertise. In primary health 
care the incremental part of health-care costs was assessed based on the patient 
questionnaire and patient registry data from municipalities.  
In Study IV, all costs accrued within the previous six-month period were included as the aim 
was to assess BC, PC and CRC patients’ total economic burden. 
4.5 STATISTICAL ANALYSIS 
The descriptive statistics for continuous variables are reported as means, standard errors 
and ranges. These were cross-tabulated based on patients’ background characteristics and 
disease state. The 95% confidence intervals were also calculated.  
In Studies I and III we imputed missing 15D responses if no more than three values were 
missing by using linear regression. The HRQoL scores from all instruments and EORTC 
symptom and functional scales as well as the dimensions of 15D were reported graphically 
by disease state or cancer. In both studies a linear multivariate model using ordinary least 
square (OLS) was built to understand the factors associated with the 15D, EQ-5D, and VAS 
scores. We ran the analysis as a stepwise selection using standardized coefficients. The fit of 
the regression models used was assessed based on adjusted R2. We examined the amount 
of collinearity using the statistical factor of tolerance and variance inflation (VIF). In Study I 
the analysis was done in two steps: the first model included as potential predictors clinical 
and general background factors, and in the second phase we added EORTC QLQ-C30 
symptom variables. In Study III all cancer types were pooled together and the regression 
model included as explanatory variables (in addition to general background variables): time 
from diagnosis; time from metastasis; time to death; hospice care; appearance of brain, 
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bone, liver or lung metastases; and oncological treatments given within the last 3 months; 
as well as EORTC QLQ-C30 symptoms. 
In Study I the mean HRQoL scores from 15D and EQ-5D were compared to those of the 
control population using Student’s independent samples t-test. The control population was 
standardized based on age, gender and education. 
In Study II we analysed, by using log linear multivariate analysis, how different background 
factors, such as cohabiting, age, gender, education level, and tumour site and HRQoL score, 
measured by the 15D, are associated with total cost. The distribution of cost variables was 
heavily skewed to the right, so a natural logarithm transformation was performed for the 
total cost variable. In the analysis, we used the fixed-model method with four different 
models per disease state (primary treatment state; remission and rehabilitation; metastatic 
disease; palliative care). 
In Study IV we calculated the components of out-of-pocket (OOP) payments and grouped 
the patients into four categories based on their assessment of the severity of financial 
difficulties (financial difficulties 0−3). We compared the HRQoL scores from 15D and EQ-5D 
from groups 1 to 3 to group 0 with no financial difficulties using Student’s t-test. To analyse 
how sociodemographic and cancer-related variables are associated with financial difficulties 
and HRQoL, we built a path model with two endogenous variables (financial difficulties and 
HRQoL). In the model, the exogenous explanatory variables were age, high education, 
employment status, marital status, type of work, total direct health-care costs, OOP 
payments, and the disease states for three cancer types, and comorbidity. The path 
coefficients (standardized beta coefficients) were estimated by two stepwise linear 
regression models (for financial difficulties and for 15D score). We calculated the indirect 
effect of an explanatory variable on the 15D score by multiplying the direct effects of each 
variable by the direct effect of financial difficulties on the 15D score.  
The analyses were performed with the SPSS 21 software (SPSS Inc., Chicago, IL, USA). All p-
values calculated were two-tailed and if less than 0.05 were considered statistically 
significant. 
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4.6 ETHICAL CONSIDERATIONS 
The study did not affect the normal routines of care, but as patients participated in the study 
by answering the questionnaire, an approval from the Ethics Committee of Helsinki 
University Central Hospital was obtained (registration number 111/13/03/02/09). Patients 
were asked to give their written informed consent before inclusion. An approval from all 
register holders (Social Insurance Institution, home municipalities, Statistics of Finland) was 
also requested before access to data was granted. The trial has been registered in the 
Helsinki and Uusimaa Hospital District Register (www.hus.fi) with trial number 233895.
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5 RESULTS 
Altogether 1978 breast cancer (840), prostate (630), and colorectal cancer (508) patients 
satisfied the inclusion criteria and participated in this cross-sectional study as summarized in 
Table 1. Studies I and II focus only on CRC patients across all disease states and in Studies III 
and IV also breast and prostate cancer patients were included. A majority of the patients 
(77%) had local disease, 19% had metastatic disease and only 4% were in the palliative care 
phase. PC patients were on average oldest (69 years) and BC patients youngest (62 years). In 
general, participants were well educated: 57% had a higher education defined as at least 
high school completed; 53% were white collar workers, but two-thirds were already retired; 
70% were married or co-habiting. 
Drop-out analysis 
In total, 3278 patients were approached of whom 2032 responded. The total response rate 
was 62%. Only age is available from those that did not respond. The mean age (66) did not 
differ statistically significantly between the groups.  
The patient survey questionnaire was extensive (10 pages and 66 questions, see Appendix I) 
and 386 patients left at least one HRQoL question unanswered. The mean age of those who 
were not able to complete the questionnaire fully (70 years) was statistically significantly 
higher than of those who did complete it (65 years). 
5.1 HRQOL (STUDY I AND III) 
Health-related quality of life was assessed using the 15D, EQ-5D-3L (‘EQ-5D’) and EORTC 
QLQ-C30 instruments in Studies I and III. Study I focused only on CRC including all disease 
states and Study III included palliative patients having breast, prostate or colorectal cancer. 
HRQoL in different states of CRC (Study I) 
The HRQoL results varied substantially based on the instrument used: 15D gave the highest 
scores in all disease states (Figure 9). The mean 15D score among all patients was 0.869 with 
a range from 0.423 to 1. The mean score by EQ-5D was 0.813, with a range from –0.429 to 
1. The mean VAS score, which is a patient’s subjective valuation, was 74.6 and the range was 
from 1 to 100. 
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Figure 9.  HRQoL in different states of CRC measured by 15D, EQ-5D and VAS1. 
 
As expected, the mean HRQoL was lowest among palliative care patients measured by all the 
instruments. According to VAS and EQ-5D, the HRQoL improved after primary treatments, 
being highest in the remission group. 
The proportion of patients who obtained a score of 1 indicating full health, varied widely 
across the instruments: it was 41% for the EQ-5D, compared to 9% for the 15D and 5% for 
VAS. Such a high percentage in patient groups, where we would not expect scores indicating 
perfect health, suggests a remarkable ceiling effect, i.e. inability of an instrument to 
distinguish health states at the better end of the scale. The high ceiling effect reduces the 
sensitivity of the instrument (discriminatory power) and reduces its ability to capture 
changes in quality of life over time (responsiveness to change).  
HRQoL comparison to general population 
The EQ-5D and 15D scores were compared to those of age-, gender- and education-
standardized scores of the general population. The control group size for the EQ-5D 
 
1 VAS scores are divided by 100. 
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measured disease states was on average 4457 and for the 15D 4823. In general, the patients’ 
HRQoL was comparable to that of the general public: only in the palliative state did the scores 
differ clinically importantly and statistically significantly (Table 8). 
 
Table 8.  Patients’ HRQoL difference from age-, gender- and education-standardized 
general population1 
 Primary treatment ∆ 
Rehabilitation 
∆ 
Remission 
∆ 
Metastatic disease
∆ 
Palliative care 
∆ 
EQ-5D score -0.033 (0.230) 0.064 (0.020) 0.046 (0.002) -0.005 (0.806) -0.119 (0.019) 
15D score -0.008 (0.486) 0.015 (0.203) 0.008 (0.266) -0.016 (0.062) -0.107 (0.000) 
 
Symptoms and functionality in different states of CRC 
The 15D dimensions and cancer-specific EORTC QLQ-C30 symptoms and functional scales 
give a more precise picture of what elements of HRQoL are impacted in different states of 
the disease.  
In the palliative state, all 15D dimension scores were lower compared to earlier disease 
states. In the metastatic state, usual activity, depression, vitality and sexual activity were 
impaired (Figure 10). 
 
1 A negative/positive number indicates that the patients are on average worse off/better off than the general 
population. 
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Figure 10.  The mean 15D profile in different states of CRC. 
 
Role and physical functioning showed largest impairment of EORTC QLQ-C30 functionality 
scales in the palliative phase. The differences between disease states were moderate in 
cognitive and emotional functioning (Figure 11).  
 
Figure 11.  Mean EORTC QLQ-C30 functionality scale in different states of CRC. 
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Figure 12.  Mean EORTC QLQ-C30 symptom scale scores in different states of CRC. 
Palliative patients were most symptomatic except that diarrhoea was more prevalent among 
patients in the primary treatments group. The most frequently reported symptoms were 
fatigue, pain and insomnia (Figure 12). Among all patients, 24% reported at least some 
financial difficulties caused by cancer.  
HRQoL of end-stage disease patients (Study III) 
The total number of palliative patients who participated in the study was quite small: 27 
breast, 30 prostate, and 57 colorectal cancer patients. To understand better what the HRQoL 
in late-stage cancer is and what the factors associated with it are, we pooled all the patients 
to the same analysis. In this study, the end-stage was defined based on two criteria: patients 
who had metastatic disease and who did not receive oncological treatments any longer, or 
who died within the six months after they responded to the questionnaire, irrespective of 
the treatment given. 
Closer to death, patients’ HRQoL declined as was expected. The differences were greater 
with the EQ-5D and VAS than when using the 15D (Figure 13A). The utility values also varied 
substantially between cancer types. Patients with colorectal cancer reported the highest 
scores whereas breast cancer patients the lowest when using the EQ-5D and VAS. With the 
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15D the differences were smaller and prostate cancer patients reported the lowest values 
(Figure 13B).   
 
 
Figure 13.  End-stage patients’ mean HRQoL score by (A) time from response to death 
and (B) by cancer type. 
The most prominent symptoms among end-stage patients were fatigue and pain and their 
prevalence increased as death became closer. At least some fatigue symptoms were 
reported by 98% of the patients and pain by 82%. At least some depression was experienced 
by 64% of the patients. Physical and role functionality were most impacted when time to 
death became shorter.  
Factors influencing HRQoL 
In Studies I and III, a multivariate model was built to understand what factors were 
associated with differences in HRQoL. In colorectal cancer, across all disease states, clinical 
and socio-economic background factors explained 22−32% of the variance in HRQoL 
measured by the 15D, EQ-5D and VAS. In the first model, where only background factors 
were included, the financial difficulties had the most prominent negative impact across all 
instruments, followed by age. When adding the symptoms from EORTC QLQ-C30 to the 
model, pain and fatigue had the biggest negative effect on HRQoL. The model explained 
52−66% of the variance (R2) based on the instrument used.  
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Among end-stage patients (III), the multivariate analysis revealed that fatigue was the main 
driver associated with impaired HRQoL irrespective of the instrument used. Other 
statistically significant explanatory variables varied based on the instrument used. With the 
15D, the time from diagnosis, constipation, female gender and fatigue were negatively 
associated with HRQoL, and education and nausea and vomiting positively. Pain and fatigue 
were the only significant factors when the EQ-5D was used. With VAS, financial difficulties, 
in addition to fatigue, pain, and depression, had a negative impact on HRQoL whereas for 
the female gender, cohabiting and appetite loss were associated with higher HRQoL. The 
explanatory power of these models varied between 56 and 79%. 
5.2 COSTS OF COLORECTAL CANCER IN DIFFERENT STATES (STUDY II) 
The mean total costs caused by CRC for a six-month period varied greatly between disease 
states. They were highest during the primary treatments, followed by palliative care and 
metastatic disease. Also, the components of costs varied a lot between disease states. Direct 
health-care costs represented 47−76% of all costs and were highest in the primary 
treatments state and lowest in the remission state. Informal care made up 33% of the costs 
in the palliative phase but were less than 10% in the other states. The share of productivity 
costs ranged from 19 to 40% between states and was highest in the primary treatments 
phase (Figure 14).  
 
Figure 14.  Mean costs of CRC by state and type of the cost for a six-month period (€). 
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Direct health-care costs 
In the primary treatments phase the direct health-care costs were dominated by inpatient 
specialist care (83% of total direct costs) whereas in the metastatic phase the medication 
costs were highest (71%). In the palliative phase hospice care costs were highest (56%). The 
mean hospice care cost in the palliative phase was €4681 and it varied between patients 
from €0 to €34,626. Primary care utilization in other states was stable and more modest 
(€424−640 per patient) than palliative care where the cost per patient was €1567.  
 
 
 
 
 
 
 
 
Figure 15.  Mean direct health-care costs of CRC for a six-month period (€). 
 
Productivity losses 
Age is naturally the main driver for productivity costs, which were substantial in all disease 
states. Out of 508 respondents 308 (61%) were above the general retirement age of 65 years 
in Finland. Twenty-three per cent of all participants were working: 33% in the primary 
treatments state, 15% in the remission, 25% in the rehabilitation, 24% in the metastatic, and 
10% in the palliative care state.  
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Table 9.  Mean productivity losses in CRC by disease state for a six-month period (€). 
  Days absent from work Productivity loss Total (95% CI) 
  Sick leave Early retirement Sick leave Early retirement  
Primary treatments 27 9 3895 1203 5098 (2979;7217) 
Rehabilitation 1 2 96 310 405 (0;1171) 
Remission 0 8 3 1127 1130 (443;1818) 
Metastatic disease 8 23 1057 3108 4165 (2568;5762) 
Palliative care 0 32 0 4271 4271 (20;8522) 
 
In the primary disease state, the productivity loss was mostly caused by sick leave due to 
cancer and in the metastatic and palliative care state by early retirement due to cancer. On 
average, the patients were on sick leave 27 days during primary treatments, 8 days during 
the metastatic disease and not at all during the other states. Among all respondents 7% were 
on early retirement due to CRC. This share was highest among metastatic (13%) and palliative 
(19%) states. (Table 9) 
Informal care 
Across all the disease states, 103 patients (20%) reported that they had received at least 
some informal care from their family or friends during the previous three months. Among 
those who co-habited, almost half (46%) reported that they had received some help. In the 
palliative state, 46% of patients were getting informal care whereas in the rehabilitation 
state this figure was only 4%. The hourly support per patient was 10.2 in the palliative and 
4.3 in the metastatic, 1.7 in the primary treatments state and less than 1 in the rehabilitation 
and remission groups (Table 10).  
 
 Table 10.  Mean informal care costs due to CRC by disease state for a six-month period 
 
N Received informal care 
(%, share of all patients) 
Mean hours of informal 
care per week 
Cost of informal care, € 
(95% CI) 
Primary 61 19 (31) 1.7 857 (158;1557) 
Rehabilitation 79 3 (4) 0.2 99 (0;206) 
Remission 217 21 (10) 0.5 232 (80;384) 
Metastatic 110 41 (37) 4.3 2 098 (988;3208) 
Palliative 41 19 (46) 10.2 7 184 (0;15157) 
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5.3 COSTS TO PATIENTS (STUDY IV) 
The financial burden of cancer is caused by the out-of-pocket (OOP) payments (medicine co-
pays, hospital and doctor fees, and travelling costs) and reduction of income due to disability 
to work. Study IV focuses on OOP payments and patients’ own assessment of their financial 
difficulties. The mean (OOP) payments for a six-month period were €267 in the primary 
treatments group, €275 in the rehabilitation group, €243 in the remission group, €369 in the 
metastatic group, and €538 in the palliative care group, respectively. OOP represented 3−8% 
of the total cost of cancer depending on the disease state. The financial burden caused by 
OOPs was clearly highest in the palliative state group and was driven by increased use of 
primary and secondary health care. The co-pays from outpatient medication were the 
biggest contributor across all disease states (28−42%) followed by private health-care co-
pays (11−28%) (Figure 16).  
 
 
Figure 16.  Mean out-of-pocket payments in different disease states by category (6-
month time, €). 
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The share of OOP payments from total costs varied from 3 to 10% and was highest in the 
remission group where total costs and health-care utilization were lowest. The total OOP 
payments for a six-month period varied from 0 to €2901 per patient.  
In the metastatic and palliative disease phases, 17% of the patients were on early retirement 
due to cancer. This was most common among BC patients (25%). Among patients with local 
disease, less than 5% were retired due to cancer. Out of those who worked, 83% felt that 
their ability to work was normal. Among patients with advanced cancer, 63% felt the same.  
Financial difficulties 
Twenty per cent of the patients reported at least some financial difficulties due to their 
cancer. This varied between disease states and was highest in the palliative group (45%), 
followed by the metastatic (30%) and primary treatments (22%) groups. In rehabilitation and 
remission groups, less than 20% had financial difficulties.   
Financial difficulties are clearly linked to impaired HRQoL. In the group that reported no 
financial difficulties by EORTC QLQ-C30, the mean 15D, EQ-5D and VAS scores were 0.896, 
0.872 and 79.1, respectively. In the group that reported a lot of financial difficulties, the 
mean 15D, EQ-5D and VAS scores were 0.714, 0.451 and 49.9, respectively. Compared to the 
group with no financial difficulties, the differences were statistically significant and clinically 
important. 
A path model was built to assess the direct and indirect effects of financial difficulties on 
HRQoL (measured by 15D). In the model, age, co-habiting, and higher education had a 
significant direct negative association with financial difficulties, whereas unemployment, 
total health-care costs (excluding OOP payments) and OOP payments had a positive 
association. Age, higher education, total health-care costs (excluding OOP payments) and 
OOP payments had a direct negative impact on HRQoL, whereas colorectal cancer had a 
positive association. Financial difficulties had a substantial direct impact on HRQoL: -
0.408(Figure 17).  
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Figure 17.  HRQoL – financial difficulties path model.1  
 
 
 
 
1 Model presents the direct and indirect effects of socio-economic and clinical factors on financial difficulties and 
HRQoL (15D score) and the total effect of financial difficulties on the 15D score. Red lines present the association 
of a single explanatory variable with financial difficulties and blue lines the association with the 15D score. 
Standardized coefficients from linear regression models were used.  
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6 DISCUSSION  
Understanding current costs and HRQoL implications of a disease provides an essential basis 
for making decisions to introduce new treatment options. Health economics provides tools 
to analyse how health-care resources are used and how scarce resources should be allocated 
to maximize health. This study aimed to: assess HRQoL in different states of CRC and define 
its determinants; evaluate end-stage cancer patients’ HRQoL; explore what resource use and 
costs are associated with CRC in different states of the disease; and to establish what is the 
financial burden of cancer to patients and what are its HRQoL implications.  
Cancer, especially CRC incidence and mortality continues to rise and the burden to society 
and to patients is substantial. CRC survival rates have improved massively during the past 
decades due to better treatment options and improved and earlier diagnostics [3]. Still, a 
significant unmet need for better treatment options remains. At the same time the cost of 
developing new therapies continues to rise driven by ever more targeted mechanisms and 
smaller patient groups. The estimated cost of developing a new prescription medicine until 
marketing approval is $2.6 billion [128]. The substantial challenges between limited health-
care budgets, increasing demand and ever more sophisticated but more expensive 
treatment options highlight the importance of this thesis.  
6.1  MAIN RESULTS 
HRQoL in different states of the disease (Study I) 
In Study I, the HRQoL among CRC patients was comprehensively assessed using two generic 
(the 15D and EQ-5D) and one cancer-specific instrument (EORTC QLQ-C30) in all states across 
the disease from diagnosis until palliative care. The study provides valuable information on 
patients’ HRQoL as it is based on real-life data and helps to identify factors that might have 
a negative impact on it.  
As expected, the HRQoL was lowest among patients in palliative care but the differences in 
other states were relatively small. The mean utility scores measured by the 15D varied from 
0.889 in the primary treatments group to 0.758 in the palliative care group (0.716–0.808). 
For EQ-5D the scores ranged from 0.850 in the remission group to 0.643 in the palliative care 
group. Among patients with local disease the HRQoL was comparable with that of a sample 
of age-, gender- and education-standardized general population controls after the primary 
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treatments phase. The study showed that the used instruments are applicable in this patient 
group but also revealed that different instruments provide very different HRQoL results and 
are not interchangeable. The 15D provided in all states the highest values, whereas patients’ 
own VAS ratings were lowest.  
The ceiling effect was substantial with the EQ-5D, as 41% of the patients obtained the score 
of full health.  The multivariate analysis revealed that pain, fatigue and financial difficulties 
are clear determinants of poor HRQoL.  
To our knowledge this is the first study in Finland to examine CRC patients’ HRQoL across all 
disease states using generic instruments. The results are comparable to a Finnish national-
level health survey where the mean score for a cancer patient was 0.855 measured by the 
15D and 0.741 by the EQ-5D [129]. Compared to Finnish PC and BC patients’ HRQoL, CRC 
patients reported lower scores at the beginning of the disease and higher in the advanced 
states [130, 131]. In a Japanese study the utility score for non-stoma long-term CRC survivor 
was 0.865 by the EQ-5D and 0.842 among patients with a stoma [12]. In a European study, 
conducted in the UK and Netherlands, the EQ-5D scores for pre-progression CRC patients 
were 0.741 and 0.731 for post-progression – clearly lower than in our study [63]. The most 
used HRQoL instrument among CRC studies is the EORTC QLQ-C30 [132]. 
Resource use and costs of CRC (Study III) 
Study III showed that direct health-care costs represent a majority of costs. Most of the 
patients were retired (65%) and thus the productivity costs were moderate: 23% on average 
across the different states. Informal care costs were substantial in the palliative phase of the 
disease, where 76% of the patients received support. 
The costs were calculated for five cross-sectional six-month periods. During the first six 
months, resource use is most intense and the costs are highest, driven by surgery and 
hospitalization. However, the most expensive phase is the metastatic phase which usually 
lasts longer. The median overall survival after metastases are diagnosed is estimated to be 
almost 30 months [133]. Thus, the metastatic phase lasts roughly five-times longer than the 
primary treatments phase and the costs are substantially higher. Longitudinal costs follow a 
U-shaped curve where the lowest costs are after the intense primary care phase.  
The direct health-care costs were on average €16,244 in the primary treatments state, €1601 
in the rehabilitation state, €1450 in the remission state, €14,277 in the metastatic state and 
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€10,004 in the palliative phase, respectively. A majority of the identified CRC cost research 
focuses on initial treatments after diagnosis with one-year follow-up. The mean cost 
estimates in US studies varied from $32,648 to $59,496 [106, 111, 134] and are clearly higher 
than what we estimated. The cost estimates in the studies conducted in Europe were 
comparable to our study. In a Dutch study the mean 90-day costs after CRC diagnosis varied 
from €13,366 to €20,865 based on the surgical technique used  [93]. A study conducted in 
Spain estimated that the mean cost of initial treatments was €8644 for stage I, €12,675 for 
stage II and €13,034 for stage III, respectively [100]. In a German study, the mean costs of 
palliative care were, for the first year €42,361, and for the second €32,023 [91]. Cost data 
distribution is usually heavily skewed, which means that a small proportion of the patients is 
causing a substantial share of the costs. The duration of the palliative phase differs between 
cancer types and the definition of palliative care varies between countries [135]. All this 
makes the cost comparison difficult.  
Torkki et al. estimated that the annual prevalence-based cost of all cancers in Finland was 
€927 million in 2014, which represents 4.5% of total health-care expenditure, and aligns with 
earlier European estimates of 3−6% of total health-care expenditure [136, 137]. In Finland 
the highest costs arise from BC, PC and CRC, which in 2014 were €367 million and of which 
CRC contributed €89 million [138]. Laudicella et al. have estimated that the direct health-
care cost per CRC is the highest among the sites listing the most common cancers [139]. CRC-
related costs are expected to continue to grow, driven mostly by an increased number of 
new patients [140]. At the same time the real cost per patient is decreasing [138]. 
HRQoL among end-stage cancer patients (Study III) 
In Study III, we analysed the HRQoL of 114 end-stage BC, PC and CRC patients using three 
different instruments (15D, EQ-5D+VAS, EORTC QLQ-C30). The HRQoL was deteriorating and 
symptom burden increased as death was approaching. The most prevalent symptoms, as 
expected based on earlier studies, were fatigue, pain and insomnia [141]. In the multivariate 
analysis the association between impaired HRQoL and fatigue was most prominent with both 
VAS and the 15D. BC patients reported the lowest utility values and their symptom burden 
measured by the EORTC QLQ-C30 was highest whereas CRC patients’ HRQoL was the highest.  
All instruments used in this study are applicable in these patient groups. Altogether 21% of 
the respondents were not able to complete the HRQoL questionnaires fully. Problems with 
reporting were most common with EORTC QLQ-C30: 19% did not complete the 
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questionnaire.  The results that the single index instruments produced varied substantially. 
The 15D provided highest values and the VAS gave the lowest. The problem with EQ-5D is 
that it cannot produce values between 0.88 and 1 and the ceiling effect is substantial. In this 
study, among end-stage cancer patients 13% obtained the score of full health with the EQ-
5D. The EQ-5D can also have negative values (worse than death) in contrast to the 15D and 
VAS.  
In the palliative care setting, generic single index value measures are not commonly used 
and thus reference values from similar patient populations are not available. The nature of 
palliative care requires more focus on patients’ own experience and, due to the short 
duration of the phase, cost-effectiveness analysis is not fully applicable in this setting [142]. 
However, symptoms and HRQoL might be useful for predicting survival in the terminal 
setting [143, 144]. To our knowledge, this is the first study to assess end-stage cancer 
patients’ HRQoL with generic instruments in Finland. As resource allocation decisions are 
more and more based on QALYs and palliative care is competing with alternative uses of the 
same resources, this study provides valuable information for decision-makers.  
Patients’ economic burden of cancer (Study IV) 
Study IV revealed the remarkable negative impact of financial difficulties on BC, PC and CRC 
patients’ HRQoL. Twenty per cent of the patients reported at least some financial difficulties 
due to their disease. The mean OOP payments for a six-month period varied from €243 in 
the remission state to €538 in the palliative care phase. Those who were unemployed, men, 
or lived alone were more likely to report health-related financial difficulties.   
In Finland the common perception is that health care is universally available, and costs 
carried by patients are small and do not restrict access to care. The direct financial burden 
for patients consists of hospital and doctor fees and medicine and travelling co-pays. In this 
study we did not assess the productivity loss to patients due to disability to work. Maximum 
co-pays and fees are regulated but the annual total ceiling of €1555 (medicine co-pay, 
travelling co-pay, hospital and primary care fees in 2019) might be challenging for many. The 
OOP payments in Finland in 2010 were $660 per capita, clearly above the OECD average of 
$521 [145].  
In Europe, a small number of studies on OOP payments are available. In an Irish study, Ó 
Céilleachair et al. estimated that the OOP payment costs for patients during the first year 
after CRC diagnosis was €1589, which is above our estimates [146]. However, there is 
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growing evidence that cancer patients in many other countries are also at a risk of financial 
difficulty and the impact it is having on patients’ HRQoL and care might be substantial [147]. 
This so-called financial toxicity is more common in countries like the US, where treatment 
costs are enormous and social security limited. Financial hardship causes stress and anxiety 
and is estimated to be the strongest independent predictor of deteriorated HRQoL among 
cancer survivors [148].  
The true costs of cancer to patients and the importance of financial difficulties might be 
underestimated in clinical practice [148, 149]. This study showed that financial stress is a 
prevalent issue in Finland among cancer patients, especially those with advanced disease, 
and needs more focus and support.  
6.2 LIMITATIONS OF THE STUDY 
Some limitations of this thesis require consideration. The most evident limitation is the cross-
sectional design. The advantage of a cross-sectional design is that it is much faster to collect 
the data from all stages of the disease compared to observational follow-up of a cohort. 
However, the cross-sectional data set does not allow the analysis of causal relationships 
between observed association of explanatory and independent variables. The design did not 
allow the analysis of how patients’ HRQoL or resource use develops over time.  
In the cross-sectional cost study (II), the costs were calculated for a six-month period only. 
This does not reveal the true costs of each state of the disease as the number of patients 
entering into each state and the duration of the state vary. This is most evident in the 
metastatic phase.  
The response rate was rather low − 62% − but comparable to other observational cross-
sectional surveys among cancer patients, where the response rate has varied between 34% 
and 79% [53, 57, 150-152]. Only age was available from non-respondents, which made a 
thorough drop-out analysis impossible. However, it is likely that patients in poor health may 
have been more likely to leave the extensive questionnaire unanswered. This risk is most 
evident among late-stage patients. Patients in the palliative care phase were mostly 
recruited from the hospice or when visiting at the palliative unit and not all patients were 
capable of completing the survey. Therefore, the HRQoL estimates might be skewed towards 
the upper end of the scale and the true HRQoL burden might be greater.  
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Although the total sample was comprehensive (n=1978), the number of patients in each 
disease-specific state was small. This was especially an issue among palliative care patients 
where the total sample size was only 74. Also, in the metastatic phase the number of 
available options and lines of treatment makes the data relatively sparse and thus 
challenging to utilize in modelling. Patients were recruited only from the Helsinki University 
Hospital region, which may limit the generalizability of the results as the treatment patterns 
and patient characteristics may not be representative for the whole of Finland.  
The choice of the statistical method for multivariate analysis is not straightforward and our 
decision to use traditional OLS could be seen as a limitation. There is an ongoing debate 
about what is the appropriate method for HRQoL scores where distributions are heavily 
skewed due to the ceiling effect [129, 153-156]. The OLS assumes normal distribution and 
thus produces biased estimates when data is censored. The study is explorative by nature 
and thus the exact quantification of the coefficients was not seen as a priority, rather the 
priority was to find drivers where to focus more on clinical setting to support patients’ 
HRQoL. Statistically more sophisticated models that take into account the censored nature 
we could have used are Tobit, which is a maximum-likelihood method, and quantile 
regression method such as CLAD (censored least absolute deviations) regression [129, 153]. 
The bias is highest with EQ-5D due to the fact that the large share of patients with full health 
was substantial. Implications and future studies 
The studies in this thesis provide much needed local information to be used in economic 
evaluations of new interventions in the treatment and prevention of CRC. This has been the 
first study to assess costs and HRQoL comprehensively across all disease states in Finland. 
The results help to detect determinants of poor HRQoL and reasons behind high costs.  
Improved survival means that patients are living longer with their disease and the relevance 
of mortality measures declines as clinical endpoints and patient-reported outcomes become 
more important. As the patients’ willingness to influence their treatment will also most likely 
increase, it is increasingly important to understand patients’ preferences, drivers of HRQoL 
and costs of possible treatment pathways. This allows health-care providers to tailor 
different patient support programmes based on patients’ individual needs and to prepare 
and manage the costs. Outcomes of care and costs should be measured routinely in health 
care and the data should be easily available to be utilized by all stakeholders in the health 
ecosystem. The results in this study showed that among patients with local disease, HRQoL 
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recovers well after primary treatments and is comparable to that of the general public. Based 
on this, the effectiveness of currently used treatments seems to be high.  
There is no common agreement on which HRQoL instrument should be used, which seems 
to be one of the main barriers to using patient-reported outcomes more widely in clinical 
trials and practice. Both generic single index measures (the 15D and EQ-5D) used here were 
applicable in this patient group. However, the 15D provided more data on symptoms and 
functionality and the statistical properties were predictable. The choice of the instrument 
might have significant impact on the results of an economic evaluation. As was seen from 
the results, the mean utility differences were smallest when using the 15D compared to EQ-
5D or VAS. In practice, that would mean that when the 15D is used instead of the EQ-5D the 
QALYs gained would be less as the utility differences between health states are smaller. This 
could mean that when using the 15D the ICERs are higher compared to EQ-5D and would 
then reduce the likelihood of implementing the new intervention to clinical practice.  
It is known that 15D compresses the utilities versus other commonly used multiattribute 
utility instruments across other disease areas as well [129, 157-160]. Richardson et al. 
compared the sensitivity and validity in their article and found that the 15D was the most 
sensitive instrument among cancer patients measured by the correlations with EORTC QLQ-
C30 in comparison to all other widely used generic utility instruments (EQ-5D-5L, HUI3, QWB, 
SF-6D, AQoL-8D) [161].  
Of those who participated in the study, 99% completed the 15D questionnaire fully, 94% the 
EQ-5D, 95% VAS, and 86% the EORT QLQ-C30, respectively. When selecting the generic 
instrument for cancer patients the number of questions does not seem to be a hurdle for 
patients. In addition, the 15D allows the utility value to be calculated even when, at 
maximum, three answers are missing. Based on this study and earlier research, 15D seems 
to be the best option to be used routinely in cancer care. To understand cancer-specific 
symptoms, also disease-specific measures such as the EORTC QLQ-C30 is useful. However, 
both costs and HRQoL are currently measured in various ways and the comparison between 
interventions and countries remains challenging.  
The articles in this thesis have been cited so far approximately 140 times in scientific articles. 
A majority of these citations are for studies I and III, which clearly shows the interest in and 
importance of focusing more on the HRQoL aspects of care.
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7 CONCLUSIONS 
x The three most common cancers, breast, prostate and colorectal, represent a 
considerable economic burden for society, and they lead to impaired HRQoL and 
premature deaths. This study generated crucial real-world data to be used in cost-
effectiveness analysis.  
x The HRQoL results depend heavily on the instrument used. HRQoL among colorectal 
cancer patients is surprisingly good compared to that of the general population across 
all disease states except for during the palliative state; this indicates the high level of 
care. The main determinants of impaired HRQoL were pain, fatigue and financial 
difficulties.  
x The costs of colorectal cancer after the diagnosis are high and mostly driven by the cost 
of surgery. Costs tend to rise again if the disease progresses. A majority of the costs are 
direct health-care costs. The share of informal care is substantial, especially in the 
palliative care state. The costs of colorectal cancer are likely to increase in the near future 
due to ageing, increasing incidence rates, improved survival, and rising treatment costs. 
x 15D, EQ-5D, VAS and EORTC QLQ-C30 are applicable instruments among end-stage 
cancer patients and provide valuable insights into patients’ HRQoL. Fatigue is the most 
significant deteriorating factor of HRQoL. The 15D produced the highest mean utility 
values in this patient group.  
x The economic burden caused by cancer-related OOP payments is high for many, which 
leads to financial difficulties. Financial difficulties have a substantial negative impact on 
patients’ HRQoL. 
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SUOSTUMUS TUTKIMUKSEEN OSALLISTUMISEEN JA 
SIINÄ KERÄTTÄVIEN HENKILÖTIETOJEN KÄSITTELYYN 
Elämänlaatu ja kustannukset rinta-, eturauhas- ja 
kolorektaalisyöpäpotilailla  
Minua on pyydetty osallistumaan yllä mainittuun tutkimukseen, jossa selvitetään kyselyn 
avulla syöpäpotilaiden elämänlaatua, kustannuksia ja oirekuvaa. Olen saanut tätä tutkimusta 
ja sen yhteydessä suoritettavaa tietojen keruuta ja käsittelyä kuvaavan tutkimustiedotteen.  
Suostun vapaaehtoisesti osallistumaan yllämainittuun tutkimukseen ja annan 
suostumukseni tutkimuksen yhteydessä tapahtuvaan tietojen keräämiseen ja niiden 
käsittelyyn. Voin myöhemmin peruuttaa suostumukseni sen vaikuttamatta mitenkään 
saamaani hoitoon.  
Annan tällä suostumuksella luvan siihen, että oheisilla kyselylomakkeilla kerätyt tiedot 
saadaan yhdistää muihin minua koskeviin Helsingin ja Uudenmaan sairaanhoitopiirissä 
oleviin hoitotietoihin sekä Tilastokeskuksen, Terveyden ja hyvinvoinnin laitoksen (THL) ja 
Kansaneläkelaitoksen (KELA) sekä kotikuntani sairauteni hoitoa koskeviin tietoihin. 
Ymmärrän, että henkilötunnuksella varustettu tieto tulee vain tutkimusryhmän tietoon ja, 
että tiedot tallennetaan erityistä salattua potilastunnusta käyttäen, jolloin niistä ei voi 
päätellä henkilöllisyyttäni. 
Suostumuksen antaja täyttää 
     
 Paikka ja aika  Allekirjoitus  
 Henkilötunnus (xxxxxx-xxx)  Sukunimi, Etunimi 
 
 
 Osoite    
 
Olkaa ystävällinen ja palauttakaa tämä suostumuslomake yhdessä 
täytetyn kyselylomakkeen kanssa.  
 
Täytetään HUS:ssa 
     
 Paikka ja aika  Suostumuksen vastaanottajan allekirjoitus  
 Nimenselvennys    
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TERVEYTEEN LIITTYVÄN ELÄMÄNLAADUN 
KYSELYLOMAKE (15D©) 
Lukekaa ensin läpi huolellisesti kunkin kysymyksen kaikki vastausvaihtoehdot. Merkitkää 
sitten rasti (x) sen vaihtoehdon kohdalle, joka parhaiten kuvaa nykyistä terveydentilaanne. 
On tärkeää, että vastaatte kaikkiin 15 kysymykseen rastittamalla kustakin yhden 
vaihtoehdon.  
Liikuntakyky  
1   Pystyn kävelemään normaalisti 
(vaikeuksitta) sisällä, ulkona ja 
portaissa. 
2   Pystyn kävelemään vaikeuksitta sisällä, 
mutta ulkona ja/tai portaissa on pieniä 
vaikeuksia. 
3   Pystyn kävelemään ilman apua sisällä 
(apuvälinein tai ilman), mutta ulkona 
ja/tai portaissa melkoisin vaikeuksin tai 
toisen avustamana. 
4   Pystyn kävelemään sisälläkin vain 
toisen avustamana. 
5  Olen täysin liikuntakyvytön ja 
vuoteenoma. 
Näkö 
1   Näen normaalisti eli näen lukea lehteä 
ja TV:n tekstejä vaikeuksitta 
(silmälaseilla tai ilman). 
2  Näen lukea lehteä ja/tai TV:n tekstejä 
pienin vaikeuksin (silmälaseilla tai 
ilman). 
3  Näen lukea lehteä ja/tai TV:n tekstejä 
huomattavin vaikeuksin (silmälaseilla 
tai ilman). 
4   En näe lukea lehteä enkä TV:n tekstejä 
ilman silmälaseja tai niiden kanssa, 
mutta näen kulkea ilman opasta. 
5   En näe kulkea oppaatta eli olen lähes 
tai täysin sokea. 
Kuulo 
1   Kuulen normaalisti eli kuulen hyvin 
normaalia puheääntä (kuulokojeella tai 
ilman). 
2   Kuulen normaalia puheääntä pienin 
vaikeuksin. 
3  Minun on melko vaikea kuulla 
normaalia puheääntä, keskustelussa 
on käytettävä normaalia kovempaa 
puheääntä. 
4   Kuulen kovaakin puheääntä heikosti; 
olen melkein kuuro. 
5  Olen täysin kuuro. 
 
Hengitys 
1   Pystyn hengittämään normaalisti eli 
minulla ei ole hengenahdistusta eikä 
muita hengitysvaikeuksia. 
2  Minulla on hengenahdistusta 
raskaassa työssä tai urheillessa, 
reippaassa kävelyssä tasamaalla tai 
lievässä ylämäessä. 
3   Minulla on hengenahdistusta, kun 
kävelen tasamaalla samaa vauhtia kuin 
muut ikäiseni. 
4   Minulla on hengenahdistusta 
pienenkin rasituksen jälkeen, esim. 
peseytyessä tai pukeutuessa. 
5  Minulla on hengenahdistusta lähes 
koko ajan, myös levossa.  
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 Nukkuminen 
1   Nukun normaalisti eli minulla ei ole 
mitään ongelmia unen suhteen. 
2   Minulla on lieviä uniongelmia, esim. 
nukahtamisvaikeuksia tai satunnaista 
yöheräilyä. 
3  Minulla on melkoisia uniongelmia, 
esim. nukun levottomasti tai uni ei 
tunnu riittävältä. 
4   Minulla on suuria uniongelmia, esim. 
joudun käyttämään usein tai 
säännöllisesti unilääkettä, herään 
säännöllisesti yöllä ja/tai aamuisin liian 
varhain. 
5   Kärsin vaikeasta unettomuudesta, 
esim. unilääkkeiden runsaasta käytöstä 
huolimatta nukkuminen on lähes 
mahdotonta, valvon suurimman osan 
yöstä. 
 Syöminen 
1   Pystyn syömään normaalisti eli itse 
ilman mitään vaikeuksia. 
2   Pystyn syömään itse pienin vaikeuksin 
(esim. hitaasti, kömpelösti, vavisten tai 
erityisapuneuvoin). 
3   Tarvitsen hieman toisen apua 
syömisessä. 
4   En pysty syömään itse lainkaan, vaan 
minua pitää syöttää. 
5   En pysty syömään itse lainkaan, vaan 
minulle pitää antaa ravintoa letkun 
avulla tai suonensisäisesti. 
Puhuminen 
1   Pystyn puhumaan normaalisti eli 
selvästi, kuuluvasti ja sujuvasti. 
2   Puhuminen tuottaa minulle pieniä 
vaikeuksia, esim. sanoja on etsittävä 
tai ääni ei ole riittävän kuuluva tai se 
vaihtaa korkeutta. 
3   Pystyn puhumaan ymmärrettävästi, 
mutta katkonaisesti, ääni vavisten, 
sammaltaen tai änkyttäen. 
4   Muilla on vaikeuksia ymmärtää 
puhettani. 
5   Pystyn ilmaisemaan itseäni vain elein.  
Eritystoiminta 
1   Virtsarakkoni ja suolistoni toimivat 
normaalisti ja ongelmitta. 
2   Virtsarakkoni ja/tai suolistoni 
toiminnassa on lieviä ongelmia, esim. 
minulla on virtsaamisvaikeuksia tai 
kova tai löysä vatsa. 
3   Virtsarakkoni ja/tai suolistoni 
toiminnassa on melkoisia ongelmia, 
esim. minulla on satunnaisia 
virtsanpidätysvaikeuksia tai vaikea 
ummetus tai ripuli. 
4   Virtsarakkoni ja/tai suolistoni 
toiminnassa on suuria ongelmia, esim. 
minulla on säännöllisesti "vahinkoja" 
tai peräruiskeiden tai katetroinnin 
tarvetta. 
5   En hallitse lainkaan virtsaamista ja/tai 
ulostamista. 
 
Tavanomaiset toiminnot 
1   Pystyn suoriutumaan normaalisti 
tavanomaisista toiminnoista (esim. 
ansiotyö, opiskelu, kotityö, vapaa-ajan 
toiminnot). 
2   Pystyn suoriutumaan tavanomaisista 
toiminnoista hieman alentuneella 
teholla tai pienin vaikeuksin. 
3   Pystyn suoriutumaan tavanomaisista 
toiminnoista huomattavasti 
alentuneella teholla tai huomattavin 
vaikeuksin tai vain osaksi. 
4   Pystyn suoriutumaan tavanomaisista 
toiminnoista vain pieneltä osin. 
5   En pysty suoriutumaan lainkaan 
tavanomaisista toiminnoista. 
   
5 
Henkinen toiminta 
1   Pystyn ajattelemaan selkeästi ja 
johdonmukaisesti ja muistini toimii 
täysin moitteettomasti. 
2   Minulla on lieviä vaikeuksia ajatella 
selkeästi ja johdonmukaisesti, tai 
muistini ei toimi täysin 
moitteettomasti. 
3   Minulla on melkoisia vaikeuksia 
ajatella selkeästi ja johdonmukaisesti, 
tai minulla on jonkin verran 
muistinmenetystä. 
4   Minulla on suuria vaikeuksia ajatella 
selkeästi ja johdonmukaisesti, tai 
minulla on huomattavaa 
muistinmenetystä. 
5   Olen koko ajan sekaisin ja vailla ajan 
tai paikan tajua. 
Vaivat ja oireet 
1   Minulla ei ole mitään vaivoja tai 
oireita, esim. kipua, särkyä, 
pahoinvointia, kutinaa jne. 
2   Minulla on lieviä vaivoja tai oireita, 
esim. lievää kipua, särkyä, 
pahoinvointia, kutinaa jne. 
3   Minulla on melkoisia vaivoja tai oireita, 
esim. melkoista kipua, särkyä, 
pahoinvointia, kutinaa jne. 
4   Minulla on voimakkaita vaivoja tai 
oireita, esim. voimakasta kipua, särkyä, 
pahoinvointia, kutinaa jne. 
5   Minulla on sietämättömiä vaivoja ja 
oireita, esim. sietämätöntä kipua, 
särkyä, pahoinvointia, kutinaa jne.  
Masentuneisuus 
1   En tunne itseäni lainkaan surulliseksi, 
alakuloiseksi tai masentuneeksi. 
2   Tunnen itseni hieman surulliseksi, 
alakuloiseksi tai masentuneeksi. 
3   Tunnen itseni melko surulliseksi, 
alakuloiseksi tai masentuneeksi. 
4   Tunnen itseni erittäin surulliseksi, 
alakuloiseksi tai masentuneeksi. 
5   Tunnen itseni äärimmäisen surulliseksi, 
alakuloiseksi tai masentuneeksi. 
Ahdistuneisuus 
1   En tunne itseäni lainkaan 
ahdistuneeksi, jännittyneeksi tai 
hermostuneeksi. 
2   Tunnen itseni hieman ahdistuneeksi, 
jännittyneeksi tai hermostuneeksi. 
3   Tunnen itseni melko ahdistuneeksi, 
jännittyneeksi tai hermostuneeksi. 
4   Tunnen itseni erittäin ahdistuneeksi, 
jännittyneeksi tai hermostuneeksi. 
5   Tunnen itseni äärimmäisen 
ahdistuneeksi, jännittyneeksi tai 
hermostuneeksi. 
Energisyys 
1   Tunnen itseni terveeksi ja 
elinvoimaiseksi. 
2   Tunnen itseni hieman uupuneeksi, 
väsyneeksi tai voimattomaksi. 
3   Tunnen itseni melko uupuneeksi, 
väsyneeksi tai voimattomaksi. 
4   Tunnen itseni erittäin uupuneeksi, 
väsyneeksi tai voimattomaksi, lähes 
"loppuun palaneeksi". 
5   Tunnen itseni äärimmäisen 
uupuneeksi, väsyneeksi tai 
voimattomaksi, täysin "loppuun 
palaneeksi". 
Sukupuolielämä 
1   Terveydentilani ei vaikeuta mitenkään 
sukupuolielämääni. 
2   Terveydentilani vaikeuttaa hieman 
sukupuolielämääni. 
3  Terveydentilani vaikeuttaa 
huomattavasti sukupuolielämääni. 
4  Terveydentilani tekee 
sukupuolielämäni lähes 
mahdottomaksi. 
5  Terveydentilani tekee 
sukupuolielämäni mahdottomaksi.  
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EORTC QLQ-C30 (VERSION 3.0)  
Selvitämme kyselyssämme joitakin teitä ja terveyttänne koskevia asioita. Pyydämme teitä 
vastaamaan itse kaikkiin kysymyksiin ympyröimällä parhaiten sopiva numero. Tässä 
kyselyssä ei ole "oikeita" eikä "vääriä" vastauksia. Pidämme antamanne tiedot ehdottoman 
luottamuksellisina. 
 
Ei 
lainkaan Vähän 
Melko 
paljon 
Hyvin 
paljon 
1. Tuntuvatko rasittavat työt kuten painavan 
ostoskassin tai matkalaukun kantaminen teistä 
työläältä? 
1 2 3 4 
2. Tuntuvatko pitkät kävelymatkat työläiltä? 1 2 3 4 
3. Tuntuvatko lyhyet kävelymatkat kotinne 
ulkopuolella työläiltä? 
1 2 3 4 
4. Pitääkö teidän pysytellä levolla tai istumassa päivän 
mittaan? 
1 2 3 4 
5. Tarvitsetteko apua ruokaillessanne, 
pukeutuessanne, peseytyessänne tai WC:n 
käytössä? 
1 2 3 4 
     
Kuluneella viikolla: Ei 
lainkaan 
Vähän Melko 
paljon 
Hyvin 
paljon 
6. Oliko teillä vaikeuksia suoriutua työstänne tai 
muista päivittäisistä toimistanne? 
1 2 3 4 
7. Oliko teillä rajoituksia harrastus- tai muissa vapaa-
ajan toiminnoissanne? 
1 2 3 4 
8. Oliko teillä hengenahdistusta? 1 2 3 4 
9. Oliko kipuja? 1 2 3 4 
10. Tunsitteko levontarvetta? 1 2 3 4 
11. Oliko unettomuutta? 1 2 3 4 
12. Tunsitteko heikotusta? 1 2 3 4 
13. Oliko ruokahaluttomuutta? 1 2 3 4 
14. Oliko pahoinvointia? 1 2 3 4 
15. Oksensitteko? 1 2 3 4 
   
7 
 
Kuluneella viikolla: 
Ei 
lainkaan 
Vähän Melko 
paljon 
Hyvin 
paljon 
16. Oliko ummetusta?  1 2 3 4 
17. Oliko ripulia? 1 2 3 4 
18. Olitteko väsynyt? 1 2 3 4 
19. Häiritsikö kipu päivittäisiä toimianne? 1 2 3 4 
20. Oliko teillä keskittymisvaikeuksia esim. 
sanomalehteä lukiessanne tai televisiota 
katsellessanne? 
1 2 3 4 
21. Olitteko jännittynyt? 1 2 3 4 
22. Olitteko huolestunut? 1 2 3 4 
23. Olitteko ärtynyt? 1 2 3 4 
24. Olitteko masentunut? 1 2 3 4 
25. Oliko teidän vaikea muistaa asioita? 1 2 3 4 
26. Häiritsikö hoito tai fyysinen kuntonne perhe-
elämäänne? 
1 2 3 4 
27. Häiritsikö hoito tai fyysinen kuntonne sosiaalista 
kanssakäymistä? 
1 2 3 4 
28. Aiheuttaako fyysinen kuntonne tai hoito 
taloudellisia vaikeuksia? 
1 2 3 4 
 
Vastatkaa seuraaviin kysymyksiin ympyröimällä numerosarjasta 1-7 teihin parhaiten 
sopiva vaihtoehto 
29. Millainen yleinen terveydentilanne oli kuluneella viikolla? 
1 2 3 4 5 6 7  
Erittäin huono Erinomainen 
 
30. Millainen yleinen elämänne laatu oli kuluneella viikolla? 
1 2 3 4 5 6 7  
Erittäin huono Erinomainen 
 
© Copyright 1995 EORTC Elämänlaadun tutkimusryhmä. Kaikki oikeudet pidätetään. Version 3.0
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TERVEYSKYSELY EQ-5D 
Olkaa hyvä ja merkitkää rastilla (x), yksi rasti kunkin alla olevan ryhmän kohdalle, mikä 
väitteistä kuvaa parhaiten terveydentilaanne tänään: 
Liikkuminen 
 Minulla ei ole vaikeuksia kävelemisessä 
 Minulla on jonkin verran vaikeuksia kävelemisessä   
 Olen vuoteenomana 
    
Itsestään huolehtiminen 
 Minulla ei ole vaikeuksia huolehtia itsestäni    
 Minulla on jonkin verran vaikeuksia peseytyä tai pukeutua itse    
 En kykene peseytymään tai pukeutumaan itse  
   
Tavanomaiset toiminnot (esim. ansiotyö, opiskelu, kotityö, vapaa-ajan toiminnot) 
 Minulla ei ole vaikeuksia suorittaa tavanomaisia toimintojani 
 Minulla on jonkin verran vaikeuksia suorittaa tavanomaisia toimintojani  
 En kykene suorittamaan tavanomaisia toimintojani     
Kivut/vaivat 
 Minulla ei ole kipuja tai vaivoja    
 Minulla on kohtalaisia kipuja tai vaivoja    
 Minulla on ankaria kipuja tai vaivoja  
   
Ahdistuneisuus/Masennus 
 En ole ahdistunut tai masentunut    
 Olen melko ahdistunut tai masentunut 
 Olen erittäin ahdistunut tai masentunut             
 
 
 
 
© 1990 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group 
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Auttaaksemme ihmisiä sanomaan, kuinka hyvä tai huono 
jokin terveydentila on, olemme piirtäneet lämpömittaria 
muistuttavan asteikon. Parasta terveydentilaa, jonka 
voitte kuvitella, merkitään siinä 100:lla ja huonointa 0:lla. 
Haluaisimme Teidän osoittavan tällä asteikolla, miten 
hyvä tai huono Teidän terveytenne on mielestänne 
tänään. Olkaa hyvä ja tehkää tämä vetämällä alla olevasta 
laatikosta viiva siihen kohtaan asteikolle, joka osoittaa, 
miten hyvä tai huono terveydentilanne on tänään. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Huonoin            
kuviteltavissa oleva  
terveydentila 
0 
Paras 
kuviteltavissa 
oleva terveydentila
Terveydentilani 
tänään 
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TAUSTAKYSYMYKSET JA RESURSSIEN KÄYTTÖ 
On tärkeää, että vastaatte kaikkiin 25 kysymykseen rastittamalla tai numeroin.
TAUSTATIEDOT 
 
1 Sukupuoli 
 Nainen 
 Mies 
2 Siviilisääty 
 Naimaton 
 Naimisissa 
 Avoliitossa 
 Leski  
3 Mikä on koulutuksenne 
(korkein loppuun suoritettu 
koulutus)? 
 Kansakoulu tai vähemmän 
 Keskikoulu tai peruskoulu 
 Ammattikoulu  
 Lukio 
 Opisto- tai 
ammattikorkeakoulutasoinen 
koulutus 
 Yliopisto tai korkeakoulu 
4 Mikä kuvaa parhaiten 
tämänhetkistä toimintaanne. 
Oletteko? 
 Kokopäivätöissä 
 Osapäivätöissä 
 Vanhuuseläkkeellä 
 Työkyvyttömyyseläkkeellä syövän 
takia  
 Työkyvyttömyyseläkkeellä tai 
varhaiseläkkeellä muun syyn 
vuoksi 
 Työtön  
 Olen poissa työelämästä muun 
syyn takia 
5 Missä ammattiasemassa olette tai 
olette viimeksi ollut työelämässä? 
 Työntekijä 
 Alempi toimihenkilö 
 Ylempi toimihenkilö 
 Yrittäjä 
 Muu 
 En ole ollut työelämässä 
6 Mikäli olette töissä, miten 
arvioisitte nykyisen työkykynne? 
 Täysin työkykyinen 
 Osittain työkyvytön 
 Täysin työkyvytön 
7 Mikäli olette työelämässä, kuinka 
monta päivää olette olleet poissa 
töistä viimeisen kolmen kuukauden 
(3 kk) aikana syövästänne johtuen? 
 
____ päivää viimeisen 3 kk aikana 
TERVEYSPALVELUIDEN 
KÄYTTÖ 
Kuinka usein olette käynyt viimeisen 
kolmen kuukauden aikana seuraavissa 
terveydenhoidon yksiköissä syöpänne 
vuoksi?  
8 Lääkärillä terveyskeskuksessa 
 
____ kertaa viimeisen 3 kk aikana 
9 Terveydenhoitajan/sairaanhoitajan 
vastaanotolla terveyskeskuksessa  
 
____ kertaa viimeisen 3 kk aikana 
10 Työpaikan työterveyslääkärillä 
 
____ kertaa viimeisen 3 kk aikana 
11 Työpaikan työterveyshoitajalla 
 
____ kertaa viimeisen 3 kk aikana 
12 Yksityisellä erikoislääkärillä 
 
____ kertaa viimeisen 3 kk aikana 
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13 Erikoislääkärillä sairaalan 
poliklinikalla 
 
____ kertaa viimeisen 3 kk aikana 
14 Erilliskäynti laboratoriossa tai 
röntgentutkimuksissa 
 
____ kertaa viimeisen 3 kk aikana 
15 Kuinka monta kertaa olette 
viimeisen kolmen kuukauden 
aikana ollut syöpänne vuoksi 
yhteydessä puhelimitse 
sairaanhoitajaan tai lääkäriin?  
 
____ kertaa viimeisen 3 kk aikana 
16 Kuinka monta kertaa olette 
viimeisen kolmen kuukauden 
aikana tavannut kotonanne 
syöpänne vuoksi 
kotisairaanhoitajan tai 
terveydenhoitajan?  
 
____ kertaa viimeisen 3 kk aikana 
17 Kuinka monta kertaa viimeisen 
kolmen kuukauden aikana 
luonanne kotona on käynyt teitä 
hoitamassa/auttamassa 
kodinhoitaja tai kotiavustaja 
syöpänne vuoksi?  
 
____ kertaa viimeisen 3 kk aikana  
18 Miten paljon olette saanut hoitoa ja 
apua perheeltänne tai ystäviltänne 
syöpänne vuoksi keskimäärin 
viikossa viimeisen kolmen 
kuukauden aikana?  
 
Keskimäärin ____ tuntia/viikossa 
viimeisen 3 kk aikana 
 
 
Kuinka monta kertaa ja vuorokautta 
(vrk) olette ollut viimeisen kolmen 
kuukauden aikana syöpänne vuoksi 
hoidossa seuraavissa paikoissa? 
19 Terveyskeskuksen vuodeosastolla  
 
____ kertaa yhteensä ____ vrk 
viimeisen  
3 kk aikana 
20 Keskus- tai yliopistosairaalassa 
 
____ kertaa yhteensä ____ vrk 
viimeisen  
3 kk aikana 
21 Muussa yleissairaalassa 
(aluesairaalassa) 
 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
22 Yksityisessä sairaalassa 
 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
23 Kuntoutuslaitoksessa 
 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
24 Kunnallis-/vanhainkodissa,  
 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
LÄÄKEMENOT 
25 Arvio, kuinka paljon olette 
käyttäneet rahaa lääkkeisiin 
viimeisen kolmen kuukauden (3 kk) 
aikana?  
 
______ € viimeisen 3 kk aikana 
 
 
Kiitos vaivannäöstänne. 
 
